Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

3.1.3.48: protein-tyrosine-phosphatase

This is an abbreviated version!
For detailed information about protein-tyrosine-phosphatase, go to the full flat file.

Word Map on EC 3.1.3.48

Reaction

[a protein]-tyrosine phosphate
+
H2O
=
[a protein]-tyrosine
 +
phosphate

Synonyms

70Z-SHP, acid phosphatase, acid phosphatase activity, acid phosphatase ortholog, acid tyrosine phosphatase, alpha-PTP-PEST, AUM, Bd1204, BDP, Bmptp-h, Brain-derived phosphatase, BVP, CAPTPase, CD148, CD148 antigen, CD45, CD45 antigen, CD45 protein tyrosine phosphatase, Cdc25 phosphatase, Cdc25-like protein, Cdc25A, Cdc25B, Cdc25B phosphatase, Cdc25C, CDK2-associated dual specificity phosphatase, Ch-1PTPase, chick retinal tyrosine phosphatase-2, cold-active protein tyrosine phosphatase, CPTP1, CQMa102 phosphatase, Cryp-2, CRYP-2/PTPRO, CRYP-2/receptor-type tyrosine-protein phosphatase O, cysteine-dependent protein tyrosine phosphatase, cyt-PTPepsilon, density-enhanced phosphatase-1, DEP-1, DEP-1 phosphatase, DLAR, dPTP61F, DSP, DSP18, dual specificity phosphatase, Dual specificity phosphatase Cdc25A, Dual specificity phosphatase Cdc25B, Dual specificity phosphatase Cdc25C, dual specificity protein phosphatase, dual specificity protein phosphatase 23, dual specificity protein phosphatase 3, Dual specificity protein phosphatase hVH1, Dual specificity protein phosphatase hVH2, Dual specificity protein phosphatase hVH3, Dual specificity protein phosphatase PYST1, Dual specificity protein phosphatase PYST2, Dual specificity protein phosphatase VHR, dual-specificity (Thr/Tyr) MAPK protein phosphatase, dual-specificity phosphatase, dual-specificity protein phosphatase, dual-specificity protein tyrosine phosphatase 18, Dual-specificity tyrosine phosphatase TS-DSP6, Dual-specificity tyrosine phosphatase YVH1, DUSP, ED-Eya2, EhPRL, EpsB, ES cell phosphatase, FAP-1, Fap1, FLP1, GLEPP-1, GLEPP1, HAP, HCP, HD-PTP, Hematopoietic cell protein-tyrosine phosphatase, Hematopoietic cell protein-tyrosine phosphatase 70Z-PEP, hematopoietic protein tyrosine phosphatase, Hematopoietic protein-tyrosine phosphatase, hematopoietic tyrosine phosphatase, HEPTP, His domain protein tyrosine phosphatase, histidine acid phosphatase, histidine domain-protein tyrosine phosphatase, HPTP beta-like tyrosine phosphatase, HPTP eta, HPTPbeta, HPTPbeta-CD, hPTPE1, IA-2, IA-2A, IA-2beta, IAR, ICAAR, IF1, IF2, insulinoma associated protein tyrosine phosphatase 2, islet cell antigen-related PTP, Islet cell autoantigen related protein, KIM-containing PTP, KIM-PTP, kinase associated phosphatase, kinase interaction motif phosphatase, kinase interaction motif-containing protein tyrosine phosphatases, L-CA, LAR, Late protein H1, LCA, LCA-related phosphatase, LDP-3, leucocyte common antigen-related protein tyrosine phosphatase, Leukocyte antigen related, leukocyte common antigen-related, LmACR2, LMJF_16_0230, LmPRL-1, LMW PTPase, LMW-PTP, LMWPTP, low molecular mass dual specificity phosphatase 3, Low molecular weight cytosolic acid phosphatase, Low molecular weight phosphotyrosine protein phosphatase, low molecular weight protein tyrosine phosphatase, low molecular weight protein-tyrosine phosphatase A, low molecular weight protein-tyrosine-phosphatase, low molecular weight-PTP, low-molecular weight PTPase, low-molecular-weight protein tyrosine phosphatase, Lpt1, LRP, Lymphoid phosphatase, lymphoid-specific tyrosine phosphatase, LyP, M1851, MAP kinase phosphatase, MAP-kinase phosphatase CPG21, MAPK-specific tyrosine phosphatase, MEG, mitogen-activated protein kinase phosphatase, mitogen-activated protein kinase phosphatase-1, mitogen-activated protein kinase-specific tyrosine phosphatase, Mitosis initiation protein, Mitosis initiation protein MIH1, Mitotic inducer homolog, MKP, MKP-1, MKP-1 like protein tyrosine phosphatase, MKP-2, MKP-3, MKP-4, MKP-5, MKP-7, MKP-X, MKP1, MKP5-C, More, MPTP, MPTP-PEST, MPtpA, MPtpB, MSP, N3PTP, NC-PTPCOM1, Neural-specific protein-tyrosine phosphatase, non-receptor protein tyrosine phosphatase, ORF5, orphan protein tyrosine phosphatase, OST-PTP, osteoclastic protein-tyrosine phosphatase, P19-PTP, p52shc, p65 PTPepsilon, p66shc, p67 PTPepsilon, P80, PC12-PTP1, PCPTP1, PEST, PGN_1525, Pgp, Phogrin, Phosphacan, phosphatase of regenerating liver-3, phosphatase, phosphoprotein (phosphotyrosine), phosphatase, phosphotyrosine, phosphoprotein phosphatase (phosphotyrosine), phosphotyrosine histone phosphatase, phosphotyrosine phosphatase, Phosphotyrosine phosphatase 13, phosphotyrosine phosphatase 1B, phosphotyrosine protein phosphatase, phosphotyrosine-specific PP, phosphotyrosylprotein phosphatase, Pmp1p, PP2A, PPase, pphA, PPM, PPT-phosphatase, PRL, PRL-1, PRL-3, PRL-related protein tyrosine phosphatase, probable low molecular weight protein-tyrosine-phosphatase, protein of regenerating liver-related protein tyrosine phosphatase, Protein phosphatase 1B, protein phosphatase 2A, protein phosphotyrosine phosphatase, protein Tyr phosphatase, protein tyrosine phosphatase, protein tyrosine phosphatase 1B, protein tyrosine phosphatase A, protein tyrosine phosphatase alpha, protein tyrosine phosphatase B, protein tyrosine phosphatase beta, protein tyrosine phosphatase epsilon, protein tyrosine phosphatase eta, protein tyrosine phosphatase H1, protein tyrosine phosphatase N12, protein tyrosine phosphatase N3, protein tyrosine phosphatase ny, Protein tyrosine phosphatase receptor-type T, protein tyrosine phosphatase SHP-1, protein tyrosine phosphatase sigma, protein tyrosine phosphatase xi, protein tyrosine phosphatase, non-receptor type 1, protein tyrosine phosphatase, receptor-type, Z polypeptide 1, protein tyrosine phosphatase-1B, protein tyrosine phosphatase-2, protein tyrosine phosphatase-BL, protein tyrosine phosphatase-H2, Protein tyrosine phosphatase-NP, protein tyrosine phosphatase-PEST, Protein-protein-tyrosine phosphatase HA2, protein-tyrosine phosphatase, Protein-tyrosine phosphatase 1B, Protein-tyrosine phosphatase 1C, Protein-tyrosine phosphatase 1E, Protein-tyrosine phosphatase 2C, Protein-tyrosine phosphatase 2E, Protein-tyrosine phosphatase 3CH134, protein-tyrosine phosphatase alpha, Protein-tyrosine phosphatase CL100, Protein-tyrosine phosphatase D1, Protein-tyrosine phosphatase ERP, Protein-tyrosine phosphatase G1, Protein-tyrosine phosphatase H1, Protein-tyrosine phosphatase LC-PTP, Protein-tyrosine phosphatase MEG1, Protein-tyrosine phosphatase MEG2, Protein-tyrosine phosphatase P19, Protein-tyrosine phosphatase PCPTP1, Protein-tyrosine phosphatase pez, Protein-tyrosine phosphatase PTP-RL10, Protein-tyrosine phosphatase PTP36, Protein-tyrosine phosphatase PTPL1, Protein-tyrosine phosphatase striatum-enriched, Protein-tyrosine phosphatase SYP, Protein-tyrosine-phosphatase SL, Protein-tyrosine-phosphate phosphohydrolase, Prp1, PrpA, PTEN, PTEN phosphoprotein phosphatase, PTK, PTP, PTP 1B, PTP epsilon, PTP IA-2beta, PTP-1B, PTP-1C, PTP-1D, PTP-2C, PTP-BAS, PTP-BL, PTP-E1, PTP-eta, PTP-F, PTP-H1, PTP-H2, PTP-HA2, PTP-like phytase, PTP-MEG2, PTP-NP, PTP-oc, PTP-PEST, PTP-phosphatase, PTP-SH2beta, PTP-SL, PTP-U2, PTP1, PTP1B, PTP1C, PTP1D, PTP1e, PTP1N13, PTP1N21, PTP2C, PTP3, PTP36, PtpA, PTPalpha, PTPase, PTPase YVH1, PTPase-MEG1, PTPase-MEG2, PtpB, PTPB1, PTPBAS, PTPbeta, PTPBR7, PTPD1, PTPepsilon, PTPepsilonC, PTPepsilonM, PTPeta, PTPetaCD, PTPG1, PTPgamma, PTPH1, PTPL1, PTPLP, PTPMEG, PTPN1, PTPN11, PTPN12, PTPN13, PTPN14, PTPN2, PTPN20 variant 15, PTPN21, PTPN22, PTPN23, PTPN3, PTPN4, PTPN4/PTP-MEG1, PTPN5, PTPN6, PTPN7, PTPN9, PTPNE6, PTPP, PTPPase, PTPPBSgamma, PTPPBSgamma-37, PTPPBSgamma-42, PTPRA, PTPRB, PTPRC, PTPRD, PTPRdelta, PTPRE, PTPRF, PTPRG, PTPRH, PTPRJ, PTPRK, PTPRM, PTPRN, PTPRN2, PTPRO, PTPRO, truncated, PTPRO-FL, PTPRomega, PTPROt, PTPRQ, PTPRR, PTPRS, PTPRT, PTPRU, PTPRV, PTPRZ, PTPRZ1, PTPS31, PTPsigma, PTPxi/RPTPbeta, PY protein phosphatase, Pyp1p, Pyp2p, R-PTP-alpha, R-PTP-beta, R-PTP-delta, R-PTP-epsilon, R-PTP-eta, R-PTP-gamma, R-PTP-kappa, R-PTP-mu, R-PTP-zeta, R2B phosphatase, receptor protein tyrosine phosphatase, receptor protein tyrosine phosphatase isoform delta, receptor protein tyrosine phosphatase isoform omega, receptor protein tyrosine phosphatase rho, receptor protein tyrosine phosphatase T, receptor protein tyrosine phosphatase {kappa}, receptor PTPepsilon, Receptor-linked protein-tyrosine phosphatase 10D, Receptor-linked protein-tyrosine phosphatase 99A, receptor-type protein tyrosine phosphatase J, Receptor-type protein-tyrosine phosphatase-kappa, receptor-type tyrosine-protein phosphatase R, reductant-inhibited PTPase1, RIP1, RNA/RNP complex-intereracting phosphatase, ROL B protein, RPTP, RPTP-BK, RPTPalpha, RPTPdelta, RPTPepsilon, RPTPgamma, RPTPkappa, RPTPlambda, RPTPmu, RPTPrho, RPTPrho/PTPRT, RPTPsigma, RPTPzeta, Saci-PTP, Saci0545, SAP1, Scr homology 2-containing tyrosine phosphatase, selective striatal enriched protein phosphatase, SH-PTP1, SH-PTP2, SH-PTP3, SH2 domain-containing tyrosine phosphatase-1, SH2 domain-containing tyrosine phosphatase-2, SHP, SHP-1, SHP-2, SHP1, SHP2, Siw14, Slr0328, Small tyrosine phosphatase, Small, acidic phosphotyrosine protein phosphatase, SP-PTP, Spd1837, SPD_1837, specific protein-tyrosine phosphatase, SPH-1, SPH-2, SPy_0036, SPy_0039, Src homology 2 domain-containing phosphatase-1, Src homology region 2 domain-containing phosphatase 1, Src homology-2 domain containing protein tyrosine phosphatase-1, Src homology-2 domain containing protein tyrosine phosphatase-2, STEP, STEP33, STEP46, STEP61, Stp1, striatal enriched protein tyrosine phosphatase, striatal-enriched protein-tyrosine phosphatase, striatal-enriched PTP, String protein, SynPTP, Syp, T cell protein tyrosine phosphatase, T-cell protein tyrosine phosphatase, T-cell protein-tyrosine phosphatase, T-cell PTP, T-DSP11, T200, TC PTP, TC-PTPase “, TC48, TCPTP, TCPTP/TC45, TcPTP1, testis- and skeletal-muscle-specific DSP, testis- and skeletal-muscle-specific dual specificity protein phosphatase, Testis-and skeletal-muscle-specific DSP, Tk-PTP, TK0241, TMDP, TpbA, TypPT, tyrosine O-phosphate phosphatase, tyrosine phosphatase, tyrosine phosphatase alpha, Tyrosine phosphatase CBPTP, tyrosine phosphatase epsilon, tyrosine phosphatase IA-2, tyrosine phosphatase Src homology region 2 domain-containing phosphatase 1, tyrosine phosphatase-1B, tyrosine-protein phosphatase, tyrosine-protein phosphatase non-receptor type 22, tyrosine-protein phosphatase non-receptor type 5, tyrosine-specific MAPK phosphatase, tyrosylprotein phosphatase, vaccinia H1-related PTP, VE-PTP, VHR, VHZ, Wzb, YopH, YwlE, YwqE, [phosphotyrosine]protein phosphatase

ECTree

     3 Hydrolases
         3.1 Acting on ester bonds
             3.1.3 Phosphoric-monoester hydrolases
                3.1.3.48 protein-tyrosine-phosphatase

Inhibitors

Inhibitors on EC 3.1.3.48 - protein-tyrosine-phosphatase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
((1E)-2-nitroprop-1-en-1-yl)benzene
-
50% inhibition at 0.023 mM in absence of 2-mercaptoethanol, at 0.515 mM in presence of 1 mM 2-mercaptoethanol
((2-bromo-4-((((2E)-3-phenylprop-2-en-1-yl)sulfanyl)methyl)phenyl)carbonyl)phosphonate
50% inhibition at 810 nM for wild-type, at 1290 nM for mutant S295F
((2-bromo-4-(((4-chlorobenzyl)thio)methyl)phenyl)(difluoro)methyl)phosphonate
50% inhibition at 285 nM for wild-type, at 1644 nM for mutant S295F
((2-phenyl-2-(phenylcarbonyl)propane-1,3-diyl)bis(benzene-4,1-diyl(difluoromethanediyl)))bis(phosphonate)
50% inhibition at 82 nM for wild-type, at 399 nM for mutant S295F
((4-((((3'-(acetylsulfamoyl)biphenyl-4-yl)methyl)sulfanyl)methyl)-2-bromophenyl)(difluoro)methyl)phosphonate
50% inhibition at 2.2 nM for wild-type, at 11 nM for mutant S295F
((4-((4E)-2-(1,3-benzothiazol-2-yl)-2-(1H-benzotriazol-1-yl)-5-phenylpent-4-en-1-yl)phenyl)(difluoro)methyl)phosphonate
50% inhibition at 47 nM for wild-type, at 260 nM for mutant S295F
((4-((4E)-2-(1,3-benzothiazol-2-yl)-2-(1H-benzotriazol-1-yl)-5-phenylpent-4-en-1-yl)phenyl)(fluoro)methyl)phosphonate
50% inhibition at 570 nM for wild-type, at 830 nM for mutant S295F
((4-((4E)-2-(1H-benzotriazol-1-yl)-2,5-diphenylpent-4-en-1-yl)phenyl)(difluoro)methyl)phosphonic acid
-
50% inhibition at 109 nM for isoform PTP-1B, at 95 nM for isoform TCPTP
((E)-2-nitrovinyl)benzene
-
i.e. trans-beta-nitrostyrene, slow-binding inhibitor, acting as a pY mimetic and binding to the enzyme active site to form an initial noncovalent E*I complex, followed by nucleophilic attack on the nitrostyrene nitro group by C215 of enzyme to form a reversible, covalent adduct. 50% inhibition at 0.0025 mM in absence of 2-mercaptoethanol, at 0.4 mM in presence of 1 mM 2-mercaptoethanol
(1-benzyl-3-methyl-2,3-dihydro-1H-imidazol-2-yl)(chloro)gold
-
i.e. [(BzMeIm)AuICl]
(1R,3aS,3bS,10aR,10bS,12aR)-1-[(2R)-4-carboxybutan-2-yl]-6,6,10a,12a-tetramethyl-1,2,3,3a,3b,4,6,7,10,10a,10b,11,12,12a-tetradecahydrocyclopenta[5,6]naphtho[1,2-f]indazole-9-carboxylic acid
-
-
(1R,5S,6S,6aR,7S,10S,10aS,11S)-10-(acetyloxy)-7-hydroxy-7,10a-dimethyl-4-methylidene-6-[(2-methylpropanoyl)oxy]-3-oxodecahydro-1H-1,5-methano-2-benzoxocin-11-yl 2-methylprop-2-enoate
no inhibition at 0.021 mM
(1S,3aR,8S,8aS,8bR)-4-henicosyl-1,8-dimethyl-3a-[(1E)-tricos-1-en-1-yl]-1,3a,5a,8,8a,8b-hexahydrobenzo[1,2-c:3,4-c']difuran-3,6-dione
-
-
(1S,3aS,4R,8S,8aS,8bR)-4-icosyl-1,8-dimethyl-3a-[(1E)-tricos-1-en-1-yl]-1,3a,4,8,8a,8b-hexahydrobenzo[1,2-c:3,4-c']difuran-3,6-dione
-
-
(2alpha,3alpha)-2,3-dihydroxyolean-12-en-28-oic acid
-
-
(2aS,3R,6aR,7aS,7bR,7cS)-2a-(hydroxymethyl)-3-icosyl-6a,7a-dimethyl-2a,3,6a,7a,7b,7c-hexahydrodifuro[2,3,4-cd:4',3',2'-hi][2]benzofuran-2,5-dione
-
-
(2aS,3R,6aR,7aS,7bR,7cS)-3-icosyl-6a,7a-dimethyl-2,5-dioxo-3,5,6a,7a,7b,7c-hexahydrodifuro[2,3,4-cd:4',3',2'-hi][2]benzofuran-2a(2H)-carbaldehyde
-
-
(2beta,3beta)-2,3-dihydroxyolean-12-en-28-oic acid
-
-
(2E)-1-(2'-hydroxyphenyl)-3-(1-naphthyl)-2-propen-1-one
-
76% inhibition at 0.025 mM
(2E)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
-
isolated from the CH2Cl2 extract of Glycyrrhiza inflata
(2E)-1-(2,4-dimethoxyphenyl)-3-(naphthalen-1-yl)prop-2-en-1-one
-
20% inhibition at 0.025 mM
(2E)-1-(2,4-dimethoxyphenyl)-3-(naphthalen-2-yl)prop-2-en-1-one
-
-
(2E)-1-(2,5-dimethoxyphenyl)-3-(2-naphthyl)-2-propen-1-one
-
58% inhibition at 0.025 mM
(2E)-1-(2,5-dimethoxyphenyl)-3-(naphth-1-yl)-2-propen-1-one
-
46% inhibition at 0.025 mM
(2E)-1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(3-nitrophenyl)prop-2-en-1-one
-
8% inhibition at 0.025 mM
(2E)-1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(naphthalen-1-yl)prop-2-en-1-one
-
16% inhibition at 0.025 mM
(2E)-1-(2-hydroxyphenyl)-3-(naphthalen-2-yl)prop-2-en-1-one
-
26% inhibition at 0.025 mM
(2E)-1-(3,4-dimethoxyphenyl)-3-(2-naphthyl)-2-propen-1-one
-
-
(2E)-1-(3,4-dimethoxyphenyl)-3-(naphthalen-2-yl)prop-2-en-1-one
-
68.5% inhibition at 0.025 mM
(2E)-1-(3-aminophenyl)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-hydroxyphenyl)-3-(naphthalen-1-yl)prop-2-en-1-one
-
20% inhibition at 0.025 mM
(2E)-1-(3-methoxy-4-hydroxyphenyl)-3-(2-naphthyl)-2-propen-1-one
-
-
(2E)-1-(3-methoxyphenyl)-3-(naphthalen-2-yl)prop-2-en-1-one
-
18.5% inhibition at 0.025 mM
(2E)-1-(4-aminophenyl)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(4-bromophenyl)-3-(naphthalen-1-yl)prop-2-en-1-one
-
25% inhibition at 0.025 mM
(2E)-1-(4-bromophenyl)-3-(naphthalen-2-yl)prop-2-en-1-one
-
11% inhibition at 0.025 mM
(2E)-1-(4-hydroxy-3-methoxyphenyl)-3-(naphthalen-2-yl)prop-2-en-1-one
-
39% inhibition at 0.025 mM
(2E)-1-(4-methoxyphenyl)-3-(naphthalen-1-yl)prop-2-en-1-one
-
18% inhibition at 0.025 mM
(2E)-1-[3-(benzyloxy)phenyl]-3-(5-bromo-4-hydroxy-2-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-2-[1-carbamothioyl-3-(4-nitrophenyl)-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]-1-(4-sulfophenyl)diazanide
-
-
(2E)-2-[[5-(3-carboxy-4-hydroxycyclohexa-1,5-dien-1-yl)furan-2-yl]methylidene]-1-[6-[(4-fluorophenyl)amino][1,2,5]oxadiazolo[3,4-b]pyrazin-5-yl]diazanide
-
-
(2E)-3-(1,3-benzodioxol-5-yl)-1-(2,4-dimethoxyphenyl)prop-2-en-1-one
-
8% inhibition at 0.025 mM
(2E)-3-(1,3-benzodioxol-5-yl)-1-(2,5-dimethoxyphenyl)prop-2-en-1-one
-
9% inhibition at 0.025 mM
(2E)-3-(1,3-benzodioxol-5-yl)-1-(2-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(1,3-benzodioxol-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
-
18% inhibition at 0.025 mM
(2E)-3-(1,3-benzodioxol-5-yl)-1-(3,4-dimethoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(1,3-benzodioxol-5-yl)-1-(3-nitrophenyl)prop-2-en-1-one
-
26% inhibition at 0.025 mM
(2E)-3-(1,3-benzodioxol-5-yl)-1-(4-bromophenyl)prop-2-en-1-one
-
14% inhibition at 0.025 mM
(2E)-3-(1,3-benzodioxol-5-yl)-1-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one
-
20% inhibition at 0.025 mM
(2E)-3-(1,3-benzodioxol-5-yl)-1-(4-methoxyphenyl)prop-2-en-1-one
-
6% inhibition at 0.025 mM
(2E)-3-(1,3-benzodioxol-5-yl)-1-(4-nitrophenyl)prop-2-en-1-one
-
19.5% inhibition at 0.025 mM
(2E)-3-(1,3-benzodioxol-5-yl)-1-phenylprop-2-en-1-one
-
-
(2E)-3-(3,4-dichlorophenyl)-1-(2,4,6-trimethoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(3-chlorophenyl)-1-(2,4,6-trimethoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(3-chlorophenyl)-1-(2-hydroxy-4,6-dimethoxyphenyl)prop-2-en-1-one
-
13% inhibition at 0.025 mM
(2E)-3-(3-nitrophenyl)-1-(2,4,6-trimethoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(4-hydroxy-2-methoxyphenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one
-
isolated from the CH2Cl2 extract of Glycyrrhiza inflata
(2E)-3-(5-bromo-2,4-dihydroxyphenyl)-1-[4-methoxy-3-(3-methylbut-3-en-2-yl)phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-(3-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-(3-[[(methoxycarbonyl)sulfanyl]amino]phenyl)prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-(4-butoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-(4-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[2-(dimethylamino)phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[2-(piperidin-1-yl)phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[2-[di(prop-2-en-1-yl)amino]phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[3-(3-methylbut-3-en-2-yl)-4-[(3-methylbut-2-en-1-yl)oxy]phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[3-(dimethylamino)phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[3-(piperidin-1-yl)phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[3-[di(prop-2-en-1-yl)amino]phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[4-(1H-pyrazol-1-yl)phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[4-(dimethylamino)phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[4-(methylsulfonyl)phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[4-(morpholin-4-yl)phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[4-(piperidin-1-yl)phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[4-hydroxy-3-(3-methylbut-2-en-1-yl)phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[4-hydroxy-3-(3-methylbut-3-en-2-yl)phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[4-hydroxy-3-(prop-2-en-1-yl)phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[4-methoxy-3-(3-methylbut-2-en-1-yl)phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[4-methoxy-3-(3-methylbut-3-en-2-yl)phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[4-methoxy-3-(prop-2-en-1-yl)phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[4-[(3-methylbut-2-en-1-yl)oxy]phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[4-[(4-methylphenyl)sulfonyl]phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[4-[di(prop-2-en-1-yl)amino]phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[6-(dimethylamino)-1,3-benzodioxol-5-yl]prop-2-en-1-one
-
-
(2E)-3-(naphthalen-1-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(naphthalen-1-yl)-1-(3-nitrophenyl)prop-2-en-1-one
-
12% inhibition at 0.025 mM
(2E)-3-(naphthalen-1-yl)-1-(4-nitrophenyl)prop-2-en-1-one
-
18% inhibition at 0.025 mM
(2E)-3-(naphthalen-1-yl)-1-phenylprop-2-en-1-one
-
37% inhibition at 0.025 mM
(2E)-3-(naphthalen-2-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
-
9% activation at 0.025 mM
(2E)-3-(naphthalen-2-yl)-1-(3-nitrophenyl)prop-2-en-1-one
-
16% inhibition at 0.025 mM
(2E)-3-(naphthalen-2-yl)-1-(4-nitrophenyl)prop-2-en-1-one
-
11% inhibition at 0.025 mM
(2E)-3-(naphthalen-2-yl)-1-phenylprop-2-en-1-one
-
12% inhibition at 0.025 mM
(2E)-3-[2,4-dimethoxy-5-(2-methylbut-3-en-2-yl)phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one
-
a semisynthetic licochalcone A derivative
(2E)-3-[2,4-dimethoxy-5-(2-methylbut-3-en-2-yl)phenyl]-1-(4-methoxyphenyl)prop-2-en-1-one
-
a semisynthetic licochalcone A derivative
(2E)-3-[4-hydroxy-2-methoxy-3-(3-methylbut-2-en-1-yl)phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one
-
isolated from the CH2Cl2 extract of Glycyrrhiza inflata
(2E)-3-[4-hydroxy-2-methoxy-5-(2-methylbut-3-en-2-yl)phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one
-
isolated from the CH2Cl2 extract of Glycyrrhiza inflata
(2E)-3-[4-hydroxy-2-methoxy-5-(2-methylbut-3-en-2-yl)phenyl]-1-(4-methoxyphenyl)prop-2-en-1-one
-
a semisynthetic licochalcone A derivative
(2E)-3-[4-hydroxy-2-methoxy-5-(3-methylbut-3-en-2-yl)phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one
-
isolated from the CH2Cl2 extract of Glycyrrhiza inflata
(2E)-3-[5-bromo-2-hydroxy-4-(tetrahydro-2H-pyran-2-yloxy)phenyl]-1-[4-methoxy-3-(3-methylbut-3-en-2-yl)phenyl]prop-2-en-1-one
-
-
(2E)-3-[5-bromo-2-methoxy-4-(tetrahydro-2H-pyran-2-yloxy)phenyl]-1-[4-hydroxy-3-(3-methylbut-3-en-2-yl)phenyl]prop-2-en-1-one
-
-
(2R)-2-benzyl-3-[2,6-dibromo-4-(6-bromo-5a,11a-dihydrobenzo[b]naphtho[2,3-d]furan-11-yl)phenyl]propanoic acid
-
(2Z)-2-([5-[4-(1H-tetrazol-1-yl)phenyl]furan-2-yl]methylidene)[1,3]thiazolo[3,2-a]benzimidazol-3(2H)-one
-
(2Z)-2-[[5-(2-methyl-5-nitrophenyl)furan-2-yl]methylidene][1,3]thiazolo[3,2-a]benzimidazol-3(2H)-one
-
(3alpha,5beta,8alpha,9beta,10alpha,13alpha)-3-[[(2E)-4-phenylbut-2-enoyl]oxy]kaur-16-en-18-oic acid
-
(3aR,4R,4aR,5R,8R,8aR,9S,9aR)-8-(acetyloxy)-5-hydroxy-5,8a-dimethyl-3-methylidene-4-[(2-methylpropanoyl)oxy]-2-oxododecahydronaphtho[2,3-b]furan-9-yl 3-methylbutanoate
no inhibition at 0.020 mM
(3aR,4R,4aR,5R,8R,8aS,9S,9aR)-8-(acetyloxy)-5,9-dihydroxy-5,8a-dimethyl-3-methylidene-2-oxododecahydronaphtho[2,3-b]furan-4-yl 2-methylprop-2-enoate
no inhibition at 0.025 mM
(3aR,4R,4aR,5R,8R,8aS,9S,9aR)-8-(acetyloxy)-5,9-dihydroxy-5,8a-dimethyl-3-methylidene-2-oxododecahydronaphtho[2,3-b]furan-4-yl 2-methylpropanoate
no inhibition at 0.024 mM
(3beta)-3-(acetyloxy)olean-12-en-28-oic acid
-
-
(3beta)-3-hydroxyolean-12-en-28-oic acid
-
-
(3beta)-3-hydroxyoleana-11,13(18)-dien-28-oic acid
-
-
(3S,3aR,4S,5R,7aR)-4-acetyl-7-henicosyl-3-methyl-1-oxo-7a-[(1E)-tricos-1-en-1-yl]-1,3,3a,4,5,7a-hexahydro-2-benzofuran-5-carboxylic acid
-
-
(3S,3aR,4S,7R,7aS)-4-acetyl-7-icosyl-3-methyl-1-oxo-7a-[(1E)-tricos-1-en-1-yl]-1,3,3a,4,7,7a-hexahydro-2-benzofuran-5-carboxylic acid
-
-
(3S,6S,9R)-3,6-dimethyl-9-[(R)-phenyl(phenylamino)methyl]-1,4,7-triazecane-2,5,8-trione
-
-
(3S,6S,9R,12R)-3,6,9-trimethyl-12-[(R)-phenyl(phenylamino)methyl]-1,4,7,10-tetraazacyclotridecane-2,5,8,11-tetrone
-
-
(3S,9R)-3-(4-hydroxybenzyl)-9-[(R)-phenyl(phenylamino)methyl]-1,4,7-triazecane-2,5,8-trione
-
-
(3Z)-5-bromo-3-[4-oxo-2-thioxo-3-[3-(trifluoromethyl)phenyl]-1,3-thiazolidin-5-ylidene]-1,3-dihydro-2H-indol-2-one
-
-
(4-((4E)-2-(1,3-benzothiazol-2-yl)-2-(1H-benzotriazol-1-yl)-5-phenylpent-4-en-1-yl)benzyl)phosphonate
50% inhibition at 3260 nM for wild-type, at 5030 nM for mutant S295F
(4-fluorophenyl)[[(Z)-(2,2,2-trifluoro-1-[1-(4-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-3-yl]ethylidene)amino]oxy]methanone
-
-
(4-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl]phenyl)methaneseleninic acid
-
inactivates the PTPs, e.g. YopH, by covalent modification, binds at the active site Cys403, kinetics, overview
(4aR,6aR,6bS,8aR,12aS,14aR,14bR)-8a-hydroxy-4,4,6a,6b,11,11,14b-heptamethyl-1,4a,5,6,6a,6b,7,8a,9,10,11,12,12a,14,14a,14b-hexadecahydropicene-3,8(2H,4H)-dione
-
-
(4aR,6aS,6bR,8aR,10S,12aR,12bR,14bS)-4a,10-dihydroxy-2,2,6a,6b,9,9,12a-heptamethyl-2,3,4,4a,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-octadecahydropicen-5(1H)-one
-
-
(4aS,6aS,6bR,13aR)-10-acetyl-2,2,6a,6b,9,9,13a-heptamethyl-1,2,3,4,5,6,6a,6b,7,8,8a,9,10,13,13a,13b,14,15b-octadecahydro-4aH-chryseno[1,2-f]indazole-4a-carboxylic acid
-
-
(4aS,6aS,6bR,13aR)-10-hexanoyl-2,2,6a,6b,9,9,13a-heptamethyl-1,2,3,4,5,6,6a,6b,7,8,8a,9,10,13,13a,13b,14,15b-octadecahydro-4aH-chryseno[1,2-f]indazole-4a-carboxylic acid
-
-
(4aS,6aS,6bR,13aR)-11-amino-2,2,6a,6b,9,9,13a-heptamethyl-1,3,4,5,6,6a,6b,7,8,8a,9,13,13a,13b,14,15b-hexadecahydropiceno[3,2-d][1,3]thiazole-4a(2H)-carboxylic acid
-
-
(4aS,6aS,6bR,13aR)-2,2,6a,6b,9,9,13a-heptamethyl-1,2,3,4,5,6,6a,6b,7,8,8a,9,10,13,13a,13b,14,15b-octadecahydro-4aH-chryseno[1,2-f]indazole-4a-carboxylic acid
-
-
(4aS,6aS,6bR,13aR)-2,2,6a,6b,9,9,13a-heptamethyl-1,3,4,5,6,6a,6b,7,8,8a,9,13,13a,13b,14,15b-hexadecahydropiceno[2,3-d][1,2]oxazole-4a(2H)-carboxylic acid
-
-
(4aS,6aS,6bR,13aR)-2,2,6a,6b,9,9,13a-heptamethyl-10-(pyridin-3-ylcarbonyl)-1,2,3,4,5,6,6a,6b,7,8,8a,9,10,13,13a,13b,14,15b-octadecahydro-4aH-chryseno[1,2-f]indazole-4a-carboxylic acid
-
-
(4aS,6aS,6bR,13aR)-2,2,6a,6b,9,9,13a-heptamethyl-10-(pyridin-4-ylcarbonyl)-1,2,3,4,5,6,6a,6b,7,8,8a,9,10,13,13a,13b,14,15b-octadecahydro-4aH-chryseno[1,2-f]indazole-4a-carboxylic acid
-
-
(4aS,6aS,6bR,13aR)-2,2,6a,6b,9,9,13a-heptamethyl-10-phenyl-1,2,3,4,5,6,6a,6b,7,8,8a,9,10,13,13a,13b,14,15b-octadecahydro-4aH-chryseno[1,2-f]indazole-4a-carboxylic acid
-
-
(4aS,6aS,6bR,14aR)-11-amino-2,2,6a,6b,9,9,14a-heptamethyl-1,3,4,5,6,6a,6b,7,8,8a,9,14,14a,14b,15,16b-hexadecahydrochryseno[1,2-g]quinazoline-4a(2H)-carboxylic acid
-
-
(4aS,6aS,6bR,14aR)-2,2,6a,6b,9,9,11,14a-octamethyl-1,3,4,5,6,6a,6b,7,8,8a,9,14,14a,14b,15,16b-hexadecahydrochryseno[1,2-g]quinazoline-4a(2H)-carboxylic acid
-
-
(4aS,6aS,6bR,14aR)-2,2,6a,6b,9,9,14a-heptamethyl-1,3,4,5,6,6a,6b,7,8,8a,9,14,14a,14b,15,16b-hexadecahydrochryseno[1,2-g]quinazoline-4a(2H)-carboxylic acid
(4aS,6aS,6bR,14aR)-2,2,6a,6b,9,9,14a-heptamethyl-1,3,4,5,6,6a,6b,7,8,8a,9,14,14a,14b,15,16b-hexadecahydrochryseno[1,2-g]quinoxaline-4a(2H)-carboxylic acid
-
-
(4aS,6aS,6bR,14aR)-2,2,6a,6b,9,9,14a-heptamethyl-11-(methylamino)-1,3,4,5,6,6a,6b,7,8,8a,9,14,14a,14b,15,16b-hexadecahydrochryseno[1,2-g]quinazoline-4a(2H)-carboxylic acid
-
-
(4aS,6aS,6bR,15aR)-2,2,6a,6b,9,9,15a-heptamethyl-1,2,3,4,5,6,6a,6b,7,8,8a,9,10,15,15a,15b,16,17b-octadecahydro-4aH-chryseno[2,1-b]carbazole-4a-carboxylic acid
-
-
(4aS,6aS,6bR,16aR)-2,2,6a,6b,9,9,16a-heptamethyl-1,3,4,5,6,6a,6b,7,8,8a,9,16,16a,16b,17,18b-hexadecahydrochryseno[1,2-b]phenazine-4a(2H)-carboxylic acid
-
-
(4E)-2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzylidene)-1,3-oxazol-5(4H)-one
-
-
(4R)-4-[(1R,3aS,3bS,10aR,10bS,12aR)-6,6,10a,12a-tetramethyl-1,2,3,3a,3b,4,6,6a,7,9a,10,10a,10b,11,12,12a-hexadecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-yl]pentanoic acid
-
-
(4R)-4-[(1R,3aS,3bS,10aR,10bS,12aR)-6,6,10a,12a-tetramethyl-2,3,3a,3b,4,6,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[2,3-d][1,2,3]thiadiazol-1-yl]pentanoic acid
-
-
(4R)-4-[(1R,3aS,3bS,10aR,10bS,12aR)-6,6,10a,12a-tetramethyl-2,3,3a,3b,4,6,6a,9a,10,10a,10b,11,12,12a-tetradecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d][1,2]oxazol-1-yl]pentanoic acid
-
-
(4R)-4-[(1R,3aS,3bS,10aR,10bS,12aR)-6,6,10a,12a-tetramethyl-7-phenyl-1,2,3,3a,3b,4,6,6a,7,9a,10,10a,10b,11,12,12a-hexadecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-yl]pentanoic acid
-
competitive PTP1B inhibitor
(4R)-4-[(1R,3aS,3bS,10aR,10bS,12aR)-8-amino-6,6,10a,12a-tetramethyl-2,3,3a,3b,4,6,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[2,3-d][1,3]thiazol-1-yl]pentanoic acid
-
-
(4R)-4-[(1R,3aS,3bS,11aR,11bS,13aR)-6,6,11a,13a-tetramethyl-2,3,3a,3b,4,6,11,11a,11b,12,13,13a-dodecahydro-1H-cyclopenta[5,6]naphtho[1,2-g]quinazolin-1-yl]pentanoic acid
-
-
(4R)-4-[(1R,3aS,3bS,11aR,11bS,13aR)-6,6,11a,13a-tetramethyl-2,3,3a,3b,4,6,11,11a,11b,12,13,13a-dodecahydro-1H-cyclopenta[5,6]naphtho[1,2-g]quinoxalin-1-yl]pentanoic acid
-
-
(4R)-4-[(1R,3aS,3bS,11aR,11bS,13aR)-6,6,8,11a,13a-pentamethyl-2,3,3a,3b,4,6,11,11a,11b,12,13,13a-dodecahydro-1H-cyclopenta[5,6]naphtho[1,2-g]quinazolin-1-yl]pentanoic acid
-
-
(4R)-4-[(1R,3aS,3bS,11aR,11bS,13aR)-8-amino-6,6,11a,13a-tetramethyl-2,3,3a,3b,4,6,11,11a,11b,12,13,13a-dodecahydro-1H-cyclopenta[5,6]naphtho[1,2-g]quinazolin-1-yl]pentanoic acid
-
-
(5beta,8alpha,9beta,10alpha,13alpha)-kaur-16-en-18-oic acid
-
(5R)-2-((carboxycarbonyl)amino)-5-((1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
-
(5S)-2-((carboxycarbonyl)amino)-5-((1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
-
(5Z)-3-benzyl-5-(5-bromo-4-butoxy-2-methoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
(5Z)-3-benzyl-5-[2-methoxy-5-(prop-2-en-1-yl)-4-(tetrahydro-2H-pyran-2-yloxy)benzylidene]-1,3-thiazolidine-2,4-dione
-
(5Z)-3-benzyl-5-[4-hydroxy-2-methoxy-5-(prop-2-en-1-yl)benzylidene]-1,3-thiazolidine-2,4-dione
-
(5Z)-3-butyl-5-[2-methoxy-5-(prop-2-en-1-yl)-4-(tetrahydro-2H-pyran-2-yloxy)benzylidene]-1,3-thiazolidine-2,4-dione
-
(5Z)-3-butyl-5-[4-hydroxy-2-methoxy-5-(prop-2-en-1-yl)benzylidene]-1,3-thiazolidine-2,4-dione
-
(5Z)-5-(4-hydroxy-2-methoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
(5Z)-5-(5-bromo-2,4-dimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
(5Z)-5-(5-bromo-2,4-dimethoxybenzylidene)-3-(4-methylpent-3-en-1-yl)-1,3-thiazolidine-2,4-dione
-
(5Z)-5-(5-bromo-2,4-dimethoxybenzylidene)-3-butyl-1,3-thiazolidine-2,4-dione
-
(5Z)-5-(5-bromo-2,4-dimethoxybenzylidene)-3-methyl-1,3-thiazolidine-2,4-dione
-
(5Z)-5-(5-bromo-4-butoxy-2-methoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
(5Z)-5-(5-bromo-4-butoxy-2-methoxybenzylidene)-3-(4-methylpent-3-en-1-yl)-1,3-thiazolidine-2,4-dione
-
(5Z)-5-(5-bromo-4-butoxy-2-methoxybenzylidene)-3-butyl-1,3-thiazolidine-2,4-dione
-
(5Z)-5-(5-bromo-4-hydroxy-2-methoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[2-methoxy-5-(prop-2-en-1-yl)-4-(tetrahydro-2H-pyran-2-yloxy)benzylidene]-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[2-methoxy-5-(prop-2-en-1-yl)-4-(tetrahydro-2H-pyran-2-yloxy)benzylidene]-3-(3-methylbut-2-en-1-yl)-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[2-methoxy-5-(prop-2-en-1-yl)-4-(tetrahydro-2H-pyran-2-yloxy)benzylidene]-3-(prop-2-en-1-yl)-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[2-methoxy-5-(prop-2-en-1-yl)-4-(tetrahydro-2H-pyran-2-yloxy)benzylidene]-3-(propan-2-yl)-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[2-methoxy-5-(prop-2-en-1-yl)-4-(tetrahydro-2H-pyran-2-yloxy)benzylidene]-3-methyl-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[4-(benzyloxy)-5-bromo-2-methoxybenzylidene]-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[4-(benzyloxy)-5-bromo-2-methoxybenzylidene]-3-(4-methylpent-3-en-1-yl)-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[4-(benzyloxy)-5-bromo-2-methoxybenzylidene]-3-methyl-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[4-hydroxy-2-methoxy-5-(prop-2-en-1-yl)benzylidene]-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[4-hydroxy-2-methoxy-5-(prop-2-en-1-yl)benzylidene]-3-(3-methylbut-2-en-1-yl)-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[4-hydroxy-2-methoxy-5-(prop-2-en-1-yl)benzylidene]-3-(prop-2-en-1-yl)-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[4-hydroxy-2-methoxy-5-(prop-2-en-1-yl)benzylidene]-3-(propan-2-yl)-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[4-hydroxy-2-methoxy-5-(prop-2-en-1-yl)benzylidene]-3-methyl-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[5-bromo-2-methoxy-4-(prop-2-en-1-yloxy)benzylidene]-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[5-bromo-2-methoxy-4-(prop-2-en-1-yloxy)benzylidene]-3-(4-methylpent-3-en-1-yl)-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[5-bromo-2-methoxy-4-(prop-2-en-1-yloxy)benzylidene]-3-butyl-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[5-bromo-2-methoxy-4-(propan-2-yloxy)benzylidene]-3-(4-methylpent-3-en-1-yl)-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[5-bromo-2-methoxy-4-(propan-2-yloxy)benzylidene]-3-butyl-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[5-bromo-2-methoxy-4-[(3-methylbut-2-en-1-yl)oxy]benzylidene]-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[5-bromo-2-methoxy-4-[(4-methylpent-3-en-1-yl)oxy]benzylidene]-3-(4-methylpent-3-en-1-yl)-1,3-thiazolidine-2,4-dione
-
(6aS,6bR,8aR,10S,12aS,12bR)-10-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-2,3,4,4a,6,6a,6b,7,8,8a,9,10,11,12,12a,12b-hexadecahydropicen-5(1H)-one
-
-
(6R)-6-[(R)-phenyl(phenylamino)methyl]-1,4-diazepane-2,5-dione
-
-
(7bS,9R,13bR,15R)-7-amino-9-(hydroxymethyl)-10,13-dioxo-2,3,3a,3b,4,5,6,7,7a,7b,9,10,13,13b-tetradecahydro-1H-6,8-methanobenzo[h]imidazo[1,2-a]pyrido[3,2-c][1,5]naphthyridine-15-carbonitrile
inhibits Cdc25B modestly
(7bS,9R,13bR,15S)-7-amino-15-hydroxy-9-(hydroxymethyl)-2,3,3a,3b,4,5,6,7,7a,7b,9,13b-dodecahydro-1H-6,8-methanobenzo[h]imidazo[1,2-a]pyrido[3,2-c][1,5]naphthyridine-10,13-dione
-
(9R)-9-[(R)-furan-2-yl(phenylamino)methyl]-1,4,7-triazecane-2,5,8-trione
-
-
(9R)-9-[(R)-phenyl(phenylamino)methyl]-1,4,7-triazecane-2,5,8-trione
-
-
(difluoro(4-((4E)-2-((4-fluorophenyl)carbonyl)-2-(4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)-5-phenylpent-4-en-1-yl)phenyl)methyl)phosphonic acid
-
50% inhibition at 163 nM for PTP-1B wild-type, at 1903 nM for PTP-1B mutant L119V, and at 1600 nM for isoform TCPTP wild-type and 138 nM for TCPTP mutant V121L
(difluoro[4-[(2,2,2-trifluoroethyl)carbamoyl]phenyl]methyl)phosphonic acid
-
(difluoro[4-[(2-fluorophenyl)carbamoyl]phenyl]methyl)phosphonic acid
-
(difluoro[4-[(2-phenylethyl)carbamoyl]phenyl]methyl)phosphonic acid
-
(difluoro[4-[(3-fluorophenyl)carbamoyl]phenyl]methyl)phosphonic acid
-
(difluoro[4-[(4-fluorophenyl)carbamoyl]phenyl]methyl)phosphonic acid
-
(difluoro[4-[(phenylamino)methyl]phenyl]methyl)phosphonic acid
-
(difluoro[4-[2-oxo-2-(phenylamino)ethyl]phenyl]methyl)phosphonic acid
-
(difluoro[4-[methyl(phenyl)carbamoyl]phenyl]methyl)phosphonic acid
-
(E)-N-(4,5-diphenyl-1,3-thiazol-2-yl)-2-naphthalen-2-ylethenesulfonamide
-
(E)-N-[4-(4-chlorophenyl)-5-propyl-1,3-thiazol-2-yl]-2-(3,4-dichlorophenyl)ethenesulfonamide
-
(Z)-1-(3-(3-carboxy-3-hydroxyacryloyl)benzyl)-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
-
IC50 of 2.4 mg/ml
(Z)-1-(3-(4-ethoxy-3-hydroxy-4-oxobut-2-enoyl)benzyl)-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
-
IC50 of 3.1 mg/ml
(Z)-2-(2-(5-(N-(4-chloro-3-(trifluoromethyl)benzyl)sulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl)benzoic acid
-
-
(Z)-3-(2-(2-carboxyphenyl)hydrazono)-2-oxoindoline-5-carboxylic acid
-
-
(Z)-3-(2-(2-nitrophenyl)hydrazono)-2-oxoindoline-5-sulfonic acid
-
NSC-117199
(Z)-3-(2-(3-carboxyphenyl)hydrazono)-2-oxoindoline-5-carboxylic acid
-
-
(Z)-3-(2-(5-(4-chlorobenzylcarbamoyl)-2-oxoindolin-3-ylidene)-hydrazinyl)benzoic acid
-
-
(Z)-3-(2-(5-(N-(2,4-dichlorophenethyl)sulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl)benzoic acid
-
-
(Z)-3-(2-(5-(N-(2-chlorobenzyl)sulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl)benzoic acid
-
-
(Z)-3-(2-(5-(N-(3-chloro-4-fluorobenzyl)sulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl)benzoic acid
-
-
(Z)-3-(2-(5-(N-(3-chlorobenzyl)sulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl)benzoic acid
-
-
(Z)-3-(2-(5-(N-(4-chloro-3-(trifluoromethyl)benzyl)sulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl)benzoic acid
-
-
(Z)-3-(2-(5-(N-(4-chlorobenzyl)sulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl)benzoic acid
-
-
(Z)-3-(2-(5-(N-(4-fluorobenzyl)sulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl)benzoic acid
-
-
(Z)-3-(2-(5-(N-(4-methylbenzyl)sulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl)benzoic acid
-
-
(Z)-4-(2-(5-(N-(2-chlorobenzyl)sulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl)benzoic acid
-
-
(Z)-4-(2-(5-(N-(4-chloro-3-(trifluoromethyl)benzyl)sulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl)benzoic acid
-
-
(Z)-4-(2-(5-(N-(4-chlorobenzyl)sulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl)benzoic acid
-
-
(Z)-4-(2-(5-(N-(4-fluorobenzyl)sulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl)benzoic acid
-
-
(Z)-4-(2-(5-(N-benzylsulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl) benzoic acid
-
-
([2-bromo-4-(3-oxo-2,3-diphenylpropyl)phenyl](difluoro)methyl)phosphonic acid
-
1,1'-(piperazine-1,4-diyl)bis(4-(3-(dibenzylamino)phenyl)butane-1,2,4-trione)
-
-
1,2-Cyclohexanedione
-
40% inhibition at 1 mM
1,3-difluoro-2-[(E)-2-nitroethenyl]benzene
-
50% inhibition at 0.0048 mM in absence of 2-mercaptoethanol, at 0.34 mM in presence of 1 mM 2-mercaptoethanol
1,6-dibenzyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
-
15.1% inhibition at 0.02 mg/ml
1,6-dimethyl-3-(thiophen-2-yl)pyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione
-
-
1-(1,3-benzodioxol-5-yl)-2-([1-(4-hydroxyphenyl)-1H-1,2,3,4-tetraazol-5-yl]sulfanyl)-1-ethanone
88% inhibition at 0.2 mM
1-(2,6-dihydroxy-4-methoxy-3-methylphenyl)ethanone
-
isolated from a methanol extract of the Antarctic lichen Stereocaulon alpinum
1-(4-fluorobenzyl)-6-nitro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
-
36.2% inhibition at 0.02 mg/ml
1-(4-hydroxy-3-(methoxycarbonyl)benzyl)-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
-
IC50 of 8.1 mg/ml
1-benzyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
-
15.1% inhibition at 0.02 mg/ml
1-benzyl-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
-
3.1% inhibition at 0.02 mg/ml
1-benzyl-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
-
0.7% inhibition at 0.02 mg/ml
1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
-
0.8% inhibition at 0.02 mg/ml
1-cyclopropyl-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
-
3.5% inhibition at 0.02 mg/ml
1-cyclopropyl-N-(4-fluorobenzyl)-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxamide
-
3.3% inhibition at 0.02 mg/ml
1-ethyl-3-dimethylaminopropyl carbodiimide
-
90% inhibition at 25 mM
1-ethyl-6-methyl-3-phenyl-1H-pyrimido(5,4-e)(1,2,4)triazine-5,7-dione
1-methoxy-4-((E)-2-nitrovinyl)benzene
-
50% inhibition at 0.0045 mM in absence of 2-mercaptoethanol, at 0.27 mM in presence of 1 mM 2-mercaptoethanol
1-methyl-4-((E)-2-nitrovinyl)benzene
-
50% inhibition at 0.003 mM in absence of 2-mercaptoethanol, at 0.225 mM in presence of 1 mM 2-mercaptoethanol
1-p-Bromotetramisole oxalate
-
tetramizole no effect
1-[(5Z)-5-(1-butyl-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-4-oxo-4,5-dihydro-1,3-thiazol-2-yl]piperidine-4-carboxamide
-
-
1-[4-[(2-nitrophenyl)sulfonyl]piperazin-1-yl]-2-phenoxyethanone
-
-
15-hydroxykaur-9(11),16-dien-19-oic acid
-
16alphaH,17-isovaleryloxy-ent-kauran-19-oic acid
-
diterpenoid isolated from Acanthopanax koreanum, 50% inhibition at 0.007 mM, noncompetitive
19alpha,24-dihydroxyurs-12-en-3-on-28-oic acid
-
-
2',4'-dihydroxy-1,1'-biphenyl
-
2,2'-[benzene-1,4-diylbis(methanediyloxybenzene-4,1-diyl)]bis(oxoacetic acid)
-
-
2,2-dioxo-2,3-dihydro-2-OMEGA-16-benzo (1,2,3)oxathiazole-6-carboxylic acid (5-phenylsulfanyl-1H-benzoimidazol-2-ylmethyl)-amide
2,4-dihydroxy-6-methylbenzoic acid
-
45% inhibition of PTPB1 at 0.178 mM
2,4-dimethoxy-1-((E)-2-nitrovinyl)benzene
-
50% inhibition at 0.028 mM in absence of 2-mercaptoethanol, at 0.390 mM in presence of 1 mM 2-mercaptoethanol
2,5-dihydroxy-3-[7-(2-methylbenzyl)-1H-indol-3-yl]cyclohexa-2,5-diene-1,4-dione
-
2,5-dihydroxy-3-[7-(3-methylbut-2-en-1-yl)-1H-indol-3-yl]cyclohexa-2,5-diene-1,4-dione
-
2-((carboxycarbonyl)amino)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
i.e. OATP
2-((carboxycarbonyl)amino)-5-((1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
-
2-((carboxycarbonyl)amino)-5-((4-fluoro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
-
2-((carboxycarbonyl)amino)-5-((4-hydroxy-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
-
2-((carboxycarbonyl)amino)-5-((5-hydroxy-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
-
2-(2,5-dimethyl-1H-pyrrol-1-yl)-5-hydroxybenzoic acid
-
36% residual activity at 0.1 mM; 3% residual activity at 0.1 mM; 7% residual activity at 0.1 mM; 9% residual activity at 0.1 mM
2-(4-hydroxyphenyl)-3-[(3,4-dihydroxy-1,1'-biphenyl-4-yl)methyl]-4H-1-benzopyran-4-one
-
2-(4-hydroxyphenyl)-3-[(4-carboxy-3-hydroxy-1,1'-biphenyl-4-yl)methyl]-4H-1-benzopyran-4-one
-
2-(oxalyl-amino)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid
-
2-(oxalyl-amino)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid
-
2-(oxalyl-amino)-4,7-dihydro-5H-thieno[2,3-c]thiopyran-3-carboxylic acid
-
-
2-carboperoxybenzoate
-
complete inhibition at 150 mM
2-chloro-4-(2,5-dimethyl-1H-pyrrol-1-yl) benzoic acid
-
36% residual activity at 0.1 mM; 46% residual activity at 0.1 mM; 95% residual activity at 0.1 mM; 98% residual activity at 0.1 mM
2-chloro-5-(2,5-dimethyl-1H-pyrrol-1-yl) benzoic acid
-
37% residual activity at 0.1 mM; 77% residual activity at 0.1 mM; 88% residual activity at 0.1 mM; 91% residual activity at 0.1 mM
2-hydroperoxytetrahydrofuran
-
inactivation by 2-hydroperoxytetrahydrofuran (0.05 mM, 10 min) is reversed upon reaction of the enzyme with dithiothreitol (54% return of activity, following treatment with 100 mM dthiothreitol for 1 h)
2-mercaptoethanol
-
2-[(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)imino]-1H-indene-1,3(2H)-dione
-
-
2-[(carboxycarbonyl)amino]-4,5,6,7-tetrahydro-thieno[2,3-c]-pyridine-3-carboxylic acid
i.e. TCS401, binds to the active site
2-[4,5-bis(1,3,2-dithiarsolan-2-yl)-6-hydroxy-3-oxo-3H-xanthen-9-yl]benzoic acid
i.e. FlAsH
2-[6-chloro-5-(1-naphthalyloxy)-1H-benzimidazol-2-yl]thio-N-(thiazol-2-yl)acetamide
mixed-type inhibition, 99% inhibition at 0.2 mM
24-hydroxyursolic acid
-
-
28-(10-decanoic)-oleanolic acid
-
28-(12-dodecanoic)-oleanolic acid
-
28-(2-acetic)-oleanolic acid
-
28-(4-butyric)-oleanolic acid
-
28-(6-hexanoic)-oleanolic acid
-
28-(8-octanoic)-oleanolic acid
-
28-(glycine)-oleanolic acid amide
-
28-(L-glutamic acid)-oleanolic acid amide
-
28-(L-phenylalanine)-oleanolic acid amide
-
28-(p-carboxyphenyl)-oleanolic acid amide
-
28-[4-butyric((R)-1-carboxy-phenylethyl)-amide]-DELTA12-oleanene
-
28-[4-butyric((S)-1-carboxy-3-indole-ethyl)-amide]-DELTA12-oleanene
-
28-[4-butyric((S)-1-carboxy-5-imidazole-ethyl)-amide]-DELTA12-oleanene
-
28-[4-butyric((S)-1-carboxy-methylthioethyl)-amide]-DELTA12-oleanene
-
28-[4-butyric((S)-1-carboxy-phenylethyl)-amide]-DELTA12-oleanene
-
28-[4-butyric(1-carboxy-2,3-dimethoxyphenylethyl)-amide]-DELTA12-oleanene
-
28-[4-butyric(1-carboxy-3,4-dimethoxyphenylethyl)-amide]-DELTA12-oleanene
-
28-[4-butyric(1-carboxy-3,4-oxymethyleneoxyphenylethyl)-amide]-DELTA12-oleanene
-
28-[4-butyric(1-carboxy-3,5-dimethoxyphenylethyl)-amide]-DELTA12-oleanene
-
28-[4-butyric(1-carboxy-m-chlorophenylethyl)-amide]-DELTA12-oleanene
-
28-[4-butyric(1-carboxy-m-methoxyphenylethyl)-amide]-DELTA12-oleanene
-
28-[4-butyric(1-carboxy-o-chlorophenylethyl)-amide]-DELTA12-oleanene
-
28-[4-butyric(1-carboxy-o-methoxyphenylethyl)-amide]-DELTA12-oleanene
-
28-[4-butyric(1-carboxy-o-methylphenylethyl)-amide]-DELTA12-oleanene
-
28-[4-butyric(1-carboxy-p-chlorophenylethyl)-amide]-DELTA12-oleanene
-
28-[4-butyric(1-carboxy-p-fluorophenylethyl)-amide]-DELTA12-oleanene
-
28-[4-butyric(1-carboxy-p-methoxyphenylethyl)-amide]-DELTA12-oleanene
-
28-[4-butyric(1-carboxy-p-methylphenylethyl)-amide]-DELTA12-oleanene
-
28-[4-butyric(1-carboxy-p-nitrophenylethyl)-amide]-DELTA12-oleanene
-
2alpha,3alpha,19alpha,23-tetrahydroxyurs-12-en-28-oic acid
-
50% inhibition at 0.0421 mM
2beta,3beta-2,3-dihydroxyolean-12-en-28-oic acid
-
-
3',4'-dihydroxy-1,1'-biphenyl
no inhibition of LMW-PTP isozymes, but 5% inhibition of PTP-B1 at 0.02 mM
3,16-dioxo-olean-12(13),17(18)-diene
-
-
3-((3,5-dibromo-4-hydroxyphenyl)carbonyl)-2-ethyl-N-(4-(1,3-thiazol-2-ylsulfamoyl)phenyl)-1-benzofuran-6-sulfonamide
50% inhibition of PTP1B at 0.008 mM, noncompetitive noncompetitive allosteric inhibitor, prevents formation of the active form of the enzyme by blocking the mobility of the catalytic loop
3-((3,5-dibromo-4-hydroxyphenyl)carbonyl)-2-ethyl-N-(4-sulfamoylphenyl)-1-benzofuran-6-sulfonamide
50% inhibition of PTP1B at 0.022 mM, noncompetitive allosteric inhibitor, prevents formation of the active form of the enzyme by blocking the mobility of the catalytic loop
3-(1-carboxy-ethoxy)-6-chloro-benzo(b)-thiophene-2-carboxylic acid
-
-
3-(2,2'-dimethyl-carboxypropanoyloxy)-oleanolic acid
-
3-(2,5-dimethyl-1H-pyrrol-1-yl)-4-hydroxybenzoic acid
-
20% residual activity at 0.1 mM; 3% residual activity at 0.1 mM; 52% residual activity at 0.1 mM; 7% residual activity at 0.1 mM
3-(2-carboxy-benzyloxy)-oleanolic acid
-
3-(2-carboxybenzoyloxy)-oleanolic acid
-
3-(3,5-dibromo-4-hydroxybenzoyl)-2-ethyl-N,N-dimethyl-1-benzofuran-6-sulfonamide
50% inhibition of PTP1B at 0.35 mM
3-(3,5-dibromo-4-hydroxybenzoyl)-2-ethyl-N-[4-(1,3-thiazol-2-ylsulfamoyl)phenyl]-1-benzofuran-6-sulfonamide
-
3-(3,5-dibromo-4-hydroxybenzoyl)-2-ethylbenzofuran-6-sulfonic acid-(4-(thiazol-2-yl-sulfamyl)-phenyl)-amide
-
a PTP1b inhibitor, inhibit 50% tog the infectivity of Trypanosoma cruzi trypomastigotes
3-(3,5-dibromo-4-hydroxybenzoyl)-2-ethylbenzofuran-6-sulfonic acid-[4-(thiazol-2-ylsulfamyl)phenyl]-amide
i.e. BBR
3-(3-carboxy-benzyloxy)-oleanolic acid
-
3-(4-carboxy-benzyloxy)-28-[4-butyric((s)-1-carboxyphenylethyl)-amide]-DELTA12-oleanene
-
3-(4-carboxy-benzyloxy)-oleanolic acid
-
3-(4-chlorophenyl)-1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione
-
-
3-(biphenyl-4-ylmethyl)-6-hydroxy-2-(4-hydroxybenzyl)-4H-chromen-4-one
-
3-(carboxy-fluoro-methoxy)-6-chloro-benzo(b)thiophene-2-carboxylic acid
-
-
3-(carboxymethoxy)-2-naphthoic acid
-
-
3-(carboxymethoxy)-5-((cyclohexylmethyl)-amino)thieno(3,2-b)(1)benzothiophene-2-carboxylic acid
-
-
3-(carboxymethoxy)-5-(cyclohexylamino)-thieno(3,2-b)(1)benzothiophene-2-carboxylic acid
-
-
3-(carboxymethoxy)-5-chlorothieno(3,2-b)(1)benzothiophene-2-carboxylic acid
-
-
3-(carboxymethoxy)-6-((1-(ethylsulfonyl)-piperidin-4-yl)amino)thieno(3,2-b)(1)benzothiophene-2-carboxylic acid
-
-
3-(carboxymethoxy)-6-((cyclohexylmethyl)-amino)thieno(3,2-b)(1)benzothiophene-2-carboxylic acid
-
-
3-(carboxymethoxy)-6-(cyclohexylamino)-thieno(3,2-b)(1)benzothiophene-2-carboxylic acid
-
-
3-(carboxymethoxy)-6-(tetrahydro-2H-pyran-4-ylamino)thieno(3,2-b)(1)benzothiophene-2-carboxylic acid
-
-
3-(carboxymethoxy)-6-chlorothieno(3,2-b)(1)benzothiophene-2-carboxylic acid
-
-
3-(carboxymethoxy)-6-methylthieno(3,2-c)pyridine-2-carboxylic acid
-
-
3-(carboxymethoxy)benzo(b)thiophene-2-carboxylic acid
-
-
3-(carboxymethoxy)furo(2,3-b)pyridine-2-carboxylic acid
-
-
3-(carboxymethoxy)thieno(2,3-b)pyridine-2-carboxylic acid
-
reversible, competitive
3-(carboxymethoxy)thieno(3,2-b)(1)benzo-thiophene-2-carboxylic acid
-
-
3-(carboxymethoxy)thieno(3,2-b)pyridine-2-carboxylic acid
-
-
3-(carboxymethoxy)thieno(3,2-b)thiophene-2-carboxylic acid
-
-
3-([2-chloro-6-methoxy-4-[(E)-(3-oxo[1,3]thiazolo[3,2-a]benzimidazol-2(3H)-ylidene)methyl]phenoxy]methyl)benzoic acid
-
3-benzyl-7-hydroxy-2-(4-hydroxybenzyl)-4H-chromen-4-one
10% inhibition of LMW-PTP isozymes 1 and 2,no inhibition of PTP-B1, at 0.015 mM
3-benzyloxy-oleanolic acid
-
3-butyl-7-(2,4-dihydroxy-6-pentylphenoxy)-3,5-dimethoxy-2-benzofuran-1(3H)-one
-
a pseudodepsidone-type compound, isolated from a methanol extract of the Antarctic lichen Stereocaulon alpinum
3-carboxymethoxy-6-(4-hydroxyphenyl)-benzo(b)-thiophene-2-carboxylic acid
-
-
3-carboxymethoxy-6-(5-methyl-1-phenyl-1H-pyrazol-3-ylcarbamoyl)-benzo(b)thiophene-2-carboxylic acid
-
-
3-carboxymethoxy-6-chloro-benzo(b)-thiophene-2-carboxylic acid
-
-
3-carboxymethoxy-6-phenylbenzo(b)-thiophene-2-carboxylic acid
-
-
3-carboxymethoxy-6-thiophen-2-yl-benzo(b)-thiophene-2-carboxylic acid
-
-
3-carboxymethoxy-7-chloro-benzo(b)-thiophene-2-carboxylic acid
-
-
3-carboxymethoxy-7-methyl-benzo(b)-thiophene-2-carboxylic acid
-
-
3-carboxymethoxy-naphtho(1,2-b)thiophene-2-carboxylic acid
-
-
3-carboxymethoxy-thieno(3,2-c)quinoline-2-carboxylic acid
-
-
3-carboxypropanoyloxy-oleanolic acid
-
3-chlorobenzenecarboperoxoic acid
-
complete inhibition at 150 mM
3-dehydroxy-oleanolic acid
-
3-ethyl oxalyl-oleanolic acid
-
3-hydroxy-4-(methoxycarbonyl)-2,5-dimethylphenyl 3-acetyl-2,4-dihydroxy-6-methylbenzoate
-
isolated from a methanol extract of the Antarctic lichen Stereocaulon alpinum
3-hydroxy-4-(methoxycarbonyl)-5-methylphenyl 4-(beta-D-galactopyranosyloxy)-2-hydroxy-6-pentadecylbenzoate
-
-
3-methyl-2-butenal
-
95% remaining activity at 0.5 mM
3-methylene-oleanolic acid
-
3-oxalyl-oleanolic acid
-
3-oxo-oleanolic acid
-
3-[(1-butyl-1,6-dimethoxy-3-oxo-1,3-dihydro-2-benzofuran-4-yl)oxy]-4,6-dihydroxy-2-pentylbenzoic acid
-
a pseudodepsidone-type compound, isolated from a methanol extract of the Antarctic lichen Stereocaulon alpinum
3-[(2-nitrophenyl)hydrazono]-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide
-
-
3-[(2-nitrophenyl)hydrazono]-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid 4-chlorobenzylamide
-
-
3-[(3-[(E)-[3-(4-carboxybenzyl)-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl]phenoxy)methyl]benzoic acid
-
3-[(4-[(Z)-[3-(4-carboxybenzyl)-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl]phenoxy)methyl]benzoic acid
-
3-[(E)-(3-oxo[1,3]thiazolo[3,2-a]benzimidazol-2(3H)-ylidene)methyl]benzoic acid
-
3-[2,5-dimethyl-3-[(3-oxo-2,3-dihydro[1,3]thiazolo[3,2-a]benzimidazol-2-yl)methyl]-1H-pyrrol-1-yl]benzoic acid
irreversible inhibition, detailed kinetic analysis of the interaction between E4 and the catalytic domain of enzyme STEP, overview. kinact is 0.068/s
3-[3-(2,4-dichlorophenyl)propanoyl]-2-hydroxycyclohepta-2,4,6-trien-1-one
-
3-[N'-(5-isopropylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidene)-hydrazino]benzoic acid
-
-
3-[oxalyl-amino]naphthalene-2-carboxylic acid
-
3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4,6-dicarboxylic acid
-
25% residual activity at 0.1 mM; 39% residual activity at 0.1 mM; 65% residual activity at 0.1 mM; 73% residual activity at 0.1 mM
3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4,8-dicarboxylic acid
-
30% residual activity at 0.1 mM; 53% residual activity at 0.1 mM; 63% residual activity at 0.1 mM; 79% residual activity at 0.1 mM
3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-carboxylic acid
-
23% residual activity at 0.1 mM; 75% residual activity at 0.1 mM; 80% residual activity at 0.1 mM; 9% residual activity at 0.1 mM
3alpha-angeloyloxypterokaurene L3
18% inhibition at 0.024 mM
3alpha-cinnamoyloxypterokaurene L3
-
3alpha-oleanolic acid
-
3alpha-tigloyloxypterokaurene L3
no inhibition at 0.024 mM
3beta,16a,17-trihydroxy-olean-12-ene
-
-
3beta-acetoxy-17beta-hydroxy-28-norolean-12-ene
-
-
3beta-acetoxy-28-hydroxyolean-12-ene
-
-
3beta-acetoxyolean-12-en-28-acid
-
-
3beta-acetoxyolean-12-en-28-aldehyde
-
-
3beta-hydroxyolean-12-en-28-oic acid
-
-
4'-carboxy-3'-hydroxy-1,1'-biphenyl
no inhibition of LMW-PTP isozymes, but 10% inhibition of PTP-B1 at 0.02 mM
4'-[(2-butyl-1-benzofuran-3-yl)methyl]biphenyl-4-ol
-
4'-[2-(4-hydroxybutyl)-1-benzofuran-3-yl]biphenyl-4-ol
-
4,4'-[benzene-1,4-diylbis(methanediyloxy)]dibenzoic acid
-
4,6-bis(1,3,2-dithiarsolan-2-yl)-7-hydroxy-3H-phenoxazin-3-one
i.e. ReAsH
4-(((5Z)-2-(4-fluorophenylimino)-4-oxo-5-[(3-phenoxyphenyl)methylidene]thiazolidin-3-yl)methyl)benzoic acid
-
4-(((5Z)-2-(4-fluorophenylimino)-4-oxo-5-[(3-phenylmethoxyphenyl)methylidene]thiazolidin-3-yl)methyl)benzoic acid
-
4-(((5Z)-2-(4-fluorophenylimino)-4-oxo-5-[(4-phenoxyphenyl)methylidene]thiazolidin-3-yl) methyl)benzoic acid
-
4-(((5Z)-2-(4-fluorophenylimino)-4-oxo-5-[(4-phenylmethoxyphenyl)methylidene]thiazolidin-3-yl)methyl)benzoic acid
-
4-(((5Z)-4-oxo-5-[(3-phenoxyphenyl)methylidene]-2-thioxothiazolidin-3-yl)methyl)benzoic acid
-
4-(((5Z)-4-oxo-5-[(3-phenylmethoxyphenyl)methylidene]-2-thioxothiazolidin-3-yl)methyl)benzoic acid
-
4-(((5Z)-4-oxo-5-[(4-phenoxyphenyl)methylidene]-2-thioxothiazolidin-3-yl)methyl)benzoic acid
-
4-(((5Z)-4-oxo-5-[(4-phenylmethoxyphenyl)methylidene]-2-thioxothiazolidin-3-yl)methyl)benzoic acid
-
4-((3E)-1-(1H-benzotriazol-1-yl)-1-(4-(difluoro(phosphono)methyl)benzyl)-4-phenylbut-3-en-1-yl)benzoic acid
-
50% inhibition at 39 nM for wild-type PTP-1B, at 39 nM for mutant V113I, at 45 nM for mutant M114V, at 29 nM for mutant V113I/M114V, at 32 nM for mutant G117E, at 142 nM for mutant L119V, and at 87 nM for isoform TCPTP wild-type and 24 nM for isoform TCPTP mutant V121L
4-((E)-2-nitrovinyl)benzoic acid
-
50% inhibition at 0.0027 mM in absence of 2-mercaptoethanol, at 0.425 mM in presence of 1 mM 2-mercaptoethanol
4-(2,5-dimethyl-1H-pyrrol-1-yl) benzoic acid
-
63% residual activity at 0.1 mM; 6% residual activity at 0.1 mM; 88% residual activity at 0.1 mM; 9% residual activity at 0.1 mM
4-(2,5-dimethyl-1H-pyrrol-1-yl)-3-hydroxybenzoic acid
-
21% residual activity at 0.1 mM; 67% residual activity at 0.1 mM; 72% residual activity at 0.1 mM; 9% residual activity at 0.1 mM
4-(2,5-dimethyl-1H-pyrrol-1-yl)phthalic acid
-
18% residual activity at 0.1 mM; 54% residual activity at 0.1 mM; 78% residual activity at 0.1 mM; 80% residual activity at 0.1 mM
4-(3-(dibenzylamino)phenyl)-2,4-dioxobutanoic acid
-
-
4-(5-bromo-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-2-hydroxybenzoic acid
-
4-(5-[5-(3,5-dichlorophenoxy)-2-furyl]-1,2,4-oxadiazol-3-yl)phenyl-N,N-dimethylsulfamate
85% inhibition at 0.2 mM
4-(beta-D-galactopyranosyloxy)-2-hydroxy-6-pentadecylbenzoic acid
-
-
4-(difluoro(phosphono)methyl)-N-pentadecanoyl-L-phenylalanyl-L-a-aspartyl-4-(difluoro(phosphono)methyl)-L-phenylalaninamide
-
-
4-(difluoro(phosphono)methyl)-N-pentadecanoyl-L-phenylalanyl-L-alpha-aspartyl-4-(difluoro(phosphono)methyl)-L-phenylalaninamide
-
dose-dependent increase in Y527 phosphorylation of Src
4-([(2E,5Z)-2-[(4-methoxyphenyl)imino]-4-oxo-5-[(3-phenoxyphenyl)methylidene]-1,3-thiazolidin-3-yl]methyl)benzoic acid
-
4-([(2E,5Z)-2-[(4-methoxyphenyl)imino]-4-oxo-5-[(4-phenoxyphenyl)methylidene]-1,3-thiazolidin-3-yl]methyl)benzoic acid
-
4-([(2E,5Z)-2-[(4-tert-butylphenyl)imino]-4-oxo-5-[(3-phenoxyphenyl)methylidene]-1,3-thiazolidin-3-yl]methyl)benzoic acid
-
4-([(2E,5Z)-2-[(4-tert-butylphenyl)imino]-4-oxo-5-[(4-phenoxyphenyl)methylidene]-1,3-thiazolidin-3-yl]methyl)benzoic acid
-
4-([(2E,5Z)-5-[[3-(benzyloxy)phenyl]methylidene]-2-[(4-methoxyphenyl)imino]-4-oxo-1,3-thiazolidin-3-yl]methyl)benzoic acid
-
4-([(2E,5Z)-5-[[3-(benzyloxy)phenyl]methylidene]-2-[(4-tert-butylphenyl)imino]-4-oxo-1,3-thiazolidin-3-yl]methyl)benzoic acid
-
4-([(2E,5Z)-5-[[4-(benzyloxy)phenyl]methylidene]-2-[(4-methoxyphenyl)imino]-4-oxo-1,3-thiazolidin-3-yl]methyl)benzoic acid
-
4-([(2E,5Z)-5-[[4-(benzyloxy)phenyl]methylidene]-2-[(4-tert-butylphenyl)imino]-4-oxo-1,3-thiazolidin-3-yl]methyl)benzoic acid
-
4-([(5E)-5-[3-(benzyloxy)benzylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]methyl)benzoic acid
-
4-([(5Z)-2,4-dioxo-5-[(3-phenoxyphenyl)methylidene]-1,3-thiazolidin-3-yl]methyl)benzoic acid
-
4-([(5Z)-2,4-dioxo-5-[(4-phenoxyphenyl)methylidene]-1,3-thiazolidin-3-yl]methyl)benzoic acid
-
4-([(5Z)-2-(4-fluorophenylimino)-4-oxo-5-([3-(2-phenylethoxy)phenyl]methylidene)thiazolidin-3-yl]methyl)benzoic acid
-
4-([(5Z)-2-(4-fluorophenylimino)-4-oxo-5-([4-(2-phenylethoxy)phenyl]methylidene)thiazolidin-3-yl]methyl)benzoic acid
-
4-([(5Z)-4-oxo-5-[[3-(2-phenylethoxy)phenyl]methylidene)-2-thioxothiazolidin-3-yl]methyl]benzoic acid
-
4-([(5Z)-4-oxo-5-[[4-(2-phenylethoxy)phenyl]methylidene)-2-thioxothiazolidin-3-yl]methyl]benzoic acid
-
4-([(5Z)-5-[4-(benzyloxy)benzylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]methyl)benzoic acid
-
4-chloro-N-(6-ethoxy-1,3-benzothiazol-2-yl)benzenesulfonamide
-
-
4-chloro-N-(6-methoxy-1,3-benzothiazol-2-yl)benzenesulfonamide
-
-
4-chloro-N-(6-methyl-1,3-benzothiazol-2-yl)benzenesulfonamide
-
-
4-chloro-N-(6-nitro-1,3-benzothiazol-2-yl)benzenesulfonamide
-
-
4-fluoro-N-(6-nitro-1,3-benzothiazol-2-yl)benzenesulfonamide
-
-
4-fluorobenzyl-1-cyclopropyl-6-(4-fluorobenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate
-
73% inhibition at 0.02 mg/ml
4-hydroxymercuribenzoate
-
62% inhibition at 2.5 mM
4-isoavenaciolide
potent irreversible inhibitor of VHR; potent irreversible inhibitor of VHR; potent irreversible inhibitor of VHR
4-methoxy-3-(5-methoxy-1-benzofuran-6-yl)-5-(4-methoxyphenyl)isoxazole
-
4-methoxy-3-(5-methoxy-1-benzofuran-6-yl)-5-phenylisoxazole
-
4-methoxy-N-(6-methoxy-1,3-benzothiazol -2-yl)benzenesulfonamide
-
-
4-methoxy-N-(6-methyl-1,3-benzothiazol-2-yl)benzenesulfonamide
-
-
4-methoxy-N-(6-nitro-1,3-benzothiazol-2-yl)benzenesulfonamide
-
-
4-methyl-N-(6-methyl-1,3-benzothiazol-2-yl)benzenesulfonamide
-
-
4-methyl-N-(6-nitro-1,3-benzothiazol-2-yl)benzenesulfonamide
-
-
4-nitro-N-(6-nitro-1,3-benzothiazol-2-yl)benzenesulfonamide
-
-
4-nitrocatechol sulfate
-
applied from from bare and amine functionalized mesoporous silica, MCM-48, and mesoporous alumina for sustained delivery, competitive inhibition, kinetics, overview
4-nitrophenyl phosphate
substrate inhibition at higher concentrations; substrate inhibition at higher concentrations
4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.073 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
4-oxo-6,8-diphenyl-4H-chromene-3-carbaldehyde
50% inhibition at 0.0033 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases, 50% inhibition of isoform LAR above 1 mM
4-oxo-6-(2-phenyl-1-benzothien-3-yl)-4H-chromene-3-carbaldehyde
50% inhibition at 0.0062 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
4-oxo-6-phenyl-4H-chromene-3-carbaldehyde
50% inhibition at 0.014 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
4-oxo-8-(phenylsulfanyl)-1,4-dihydro-1,7-naphthyridine-3-carboxylic acid
-
4-oxo-8-phenyl-4H-chromene-3-carbaldehyde
50% inhibition at 0.016 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
4-[(1E)-3-(4-hydroxyphenyl)-3-oxoprop-1-en-1-yl]-5-methoxy-2-(2-methylbut-3-en-2-yl)phenyl acetate
-
a semisynthetic licochalcone A derivative
4-[(2,4-dihydroxy-6-pentadecylbenzoyl)oxy]-2-hydroxy-6-methylbenzoic acid
-
-
4-[(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)prop-2-enoyl]phenyl 4-bromobenzoate
-
-
4-[(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)prop-2-enoyl]phenyl 4-tert-butylbenzoate
-
-
4-[(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)prop-2-enoyl]phenyl benzoate
-
-
4-[(2E)-3-[2,4-dimethoxy-5-(2-methylbut-3-en-2-yl)phenyl]prop-2-enoyl]phenyl acetate
-
a semisynthetic licochalcone A derivative
4-[(2E)-3-[4-(acetyloxy)-2-methoxy-5-(2-methylbut-3-en-2-yl)phenyl]prop-2-enoyl]phenyl acetate
-
a semisynthetic licochalcone A derivative
4-[(2E)-3-[4-hydroxy-2-methoxy-5-(2-methylbut-3-en-2-yl)phenyl]prop-2-enoyl]phenyl acetate
-
a semisynthetic licochalcone A derivative
4-[(3-[(E)-[(2Z)-3-(4-carboxybenzyl)-4-oxo-2-(phenylimino)-1,3-thiazolidin-5-ylidene]methyl]phenoxy)methyl]benzoic acid
-
4-[(3-[(E)-[3-(4-carboxybenzyl)-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl]phenoxy)methyl]benzoic acid
-
4-[(4-[(Z)-[(2Z)-3-(4-carboxybenzyl)-4-oxo-2-(phenylimino)-1,3-thiazolidin-5-ylidene]methyl]phenoxy)methyl]benzoic acid
-
4-[(4-[(Z)-[3-(4-carboxybenzyl)-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl]phenoxy)methyl]benzoic acid
-
4-[1,3-dioxo-5-(4-oxo-4H-3,1-benzoxazin-2-yl)-1,3-dihydro-2H-isoindol-2-yl]benzoate
-
-
4-[2-[(5-chloro-1,3-benzoxazol-2-yl)sulfanyl]acetamido]benzoic acid
-
4-[4,5-di(biphenyl-4-yl)-1H-imidazol-2-yl]benzoic acid
-
-
4-[4-[(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)prop-2-enoyl]phenoxy]butanoic acid
-
-
4-[difluoro(phosphono)methyl]benzoic acid
-
4-[N'-(5-isopropylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidene)-hydrazino]benzoic acid
-
-
4-[[(2E,5Z)-2-[(4-methoxyphenyl)imino]-4-oxo-5-[[3-(2-phenylethoxy)phenyl]methylidene]-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(2E,5Z)-2-[(4-methoxyphenyl)imino]-4-oxo-5-[[4-(2-phenylethoxy)phenyl]methylidene]-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(2E,5Z)-2-[(4-tert-butylphenyl)imino]-4-oxo-5-[[3-(2-phenylethoxy)phenyl]methylidene]-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(2E,5Z)-2-[(4-tert-butylphenyl)imino]-4-oxo-5-[[4-(2-phenylethoxy)phenyl]methylidene]-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(2E,5Z)-4-oxo-5-[(3-phenoxyphenyl)methylidene]-2-(phenylimino)-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(2E,5Z)-4-oxo-5-[(4-phenoxyphenyl)methylidene]-2-(phenylimino)-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(2E,5Z)-4-oxo-5-[[3-(2-phenylethoxy)phenyl]methylidene]-2-(phenylimino)-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(2E,5Z)-4-oxo-5-[[4-(2-phenylethoxy)phenyl]methylidene]-2-(phenylimino)-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(2E,5Z)-5-[[3-(benzyloxy)phenyl]methylidene]-4-oxo-2-(phenylimino)-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(2E,5Z)-5-[[4-(benzyloxy)phenyl]methylidene]-4-oxo-2-(phenylimino)-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(2Z,5E)-5-(3-[[4-(hydroxymethyl)benzyl]oxy]benzylidene)-4-oxo-2-(phenylimino)-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(2Z,5E)-5-[3-(benzyloxy)benzylidene]-4-oxo-2-(phenylimino)-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(2Z,5Z)-5-(4-[[4-(hydroxymethyl)benzyl]oxy]benzylidene)-4-oxo-2-(phenylimino)-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(2Z,5Z)-5-[4-(benzyloxy)benzylidene]-4-oxo-2-(phenylimino)-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(5E)-5-(3-[[4-(hydroxymethyl)benzyl]oxy]benzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(5Z)-2,4-dioxo-5-[[3-(2-phenylethoxy)phenyl]methylidene]-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(5Z)-2,4-dioxo-5-[[4-(2-phenylethoxy)phenyl]methylidene]-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(5Z)-5-(4-[[4-(hydroxymethyl)benzyl]oxy]benzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(5Z)-5-[[3-(benzyloxy)phenyl]methylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(5Z)-5-[[4-(benzyloxy)phenyl]methylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
5,7-bis[(E)-2-[4-(dimethylamino)phenyl]ethenyl]-2-methyltetrazolo[1,5-a]pyrimidin-2-ium
-
-
5-(1,3,2-dithiarsolan-2-yl)-2-[(1E,3E)-3-[5-(1,3,2-dithiarsolan-2-yl)-3,3-dimethyl-1-(4-sulfobutyl)-1,3-dihydro-2H-indol-2-ylidene]prop-1-en-1-yl]-3,3-dimethyl-1-(4-sulfobutyl)-3H-indol-1-ium
i.e. AsCy3, 70% inhibition at 250 nM AsCy3, AsCy3 is capable of specifically and potently inhibiting mutant enzyme asPTP1B in the presence of a complex proteome, while AsCy3 does not inhibit wild-type PTP1B activity in a cell lysate
5-(1,3,2-dithiarsolan-2-yl)-2-[(1E,3E,5E)-5-[5-(1,3,2-dithiarsolan-2-yl)-3,3-dimethyl-1-(4-sulfobutyl)-1,3-dihydro-2H-indol-2-ylidene]penta-1,3-dien-1-yl]-3,3-dimethyl-1-(4-sulfobutyl)-3H-indol-1-ium
i.e. AsCy5
5-(2-fluoro-5-((1E)-3-[3-hydroxy-2-(methoxycarbonyl)phenoxy]prop-1-en-1-yl)phenyl)isoxazole-3-carboxylic acid
-
5-([(E)-[2-(4-chlorophenyl)-5-oxo-1,3-oxazol-4(5H)-ylidene]methyl]amino)-2-hydroxybenzoic acid
-
-
5-([1-[(2-chloro-1,3-thiazol-5-yl)methyl]-1H-indol-3-yl]methylidene)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione
-
-
5-acetylamino-2-(2,5-dimethyl-1H-pyrrol-1-yl) benzoic acid
-
45% residual activity at 0.1 mM; 46% residual activity at 0.1 mM; 82% residual activity at 0.1 mM; 94% residual activity at 0.1 mM
5-chloro-2-[methyl(methylidene)-lambda4-sulfanyl]-6-[(naphthalen-2-yl)oxy]-1H-benzimidazole
65% inhibition at 0.2 mM
5-chloro-N-[6-chloro-5-(2,3-dichlorophenoxy)-1H-benzimidazol-2-yl]-1-methyl-2-(methylthio)-1H-benz-imidazole-6-carboxamide
mixed-type inhibition, complete inhibition at 0.2 mM
5-methoxy-4-[(1E)-3-(4-methoxyphenyl)-3-oxoprop-1-en-1-yl]-2-(2-methylbut-3-en-2-yl)phenyl acetate
-
a semisynthetic licochalcone A derivative
5-[3-bromo-4-[(4-nitrobenzyl)oxy]benzylidene]pyrimidine-2,4,6(1H,3H,5H)-trione
-
-
5-[4-(3,4-dihydroisoquinolin-2(1H)-yl)-3-nitrobenzylidene]-2-thioxodihydropyrimidine-4,6(1H,5H)-dione
-
-
5-[4-[(2-chloro-6-fluorobenzyl)oxy]benzylidene]-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione
-
-
6,7-dihydroxy-2-(4-hydroxyphenyl)-3-[(1,1-biphenyl-4-yl)methyl]-4H-1-benzopyran-4-one
-
6,8-dibenzyl-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.013 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
6-((1-(benzylsulfonyl)piperidin-4-yl)amino)-3-(carboxymethoxy)thieno(3,2-b)(1)benzothiophene-2-carboxylic acid
-
-
6-((2-benzyl-1-benzothien-3-yl)methyl)-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.0032 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases, 50% inhibition of isoform LAR above 1 mM
6-((E)-1,2-diphenylvinyl)-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.0097 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
6-(1-benzothien-2-ylmethyl)-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.006 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
6-(1-benzothien-3-yl)-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.0077 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
6-(1-benzothien-3-ylmethyl)-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.06 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
6-(10-bromo-9-anthryl)-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.0025 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases, 50% inhibition of isoform LAR at 0.57 mM
6-(4-((2-benzyl-1-benzothiophen-3-yl)methyl)phenyl)-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.0011 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases, 50% inhibition of isoform LAR above 1 mM
6-(4-((2-benzyl-1-benzothiophen-3-yl)methyl)phenyl)-4-oxo-8-phenyl-4H-chromene-3-carbaldehyde
50% inhibition at 0.001 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases, 50% inhibition of isoform LAR at 0.52 mM
6-(4-(3-(3-(benzyloxy)-2-(methoxycarbonyl)phenoxy)propyl)piperazin-1-yl)-1-cyclopropyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
-
IC50 of 45.2 mg/ml
6-(4-benzylpiperazin-1-yl)-1-cyclopropyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
-
62.3% inhibition at 0.02 mg/ml
6-(9-anthryl)-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.0071 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
6-amino-1-(4-fluorobenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
-
12.4% inhibition at 0.02 mg/ml
6-benzyl-1-cyclopropyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
-
87.5% inhibition at 0.02 mg/ml
6-benzyl-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.036 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
6-biphenyl-4-yl-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.0043 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
6-biphenyl-4-yl-4-oxo-8-phenyl-4H-chromene-3-carbaldehyde
50% inhibition at 0.002 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases, 50% inhibition of isoform LAR above 1 mM
6-bromo-3-carboxymethoxy-benzo(b)-thiophene-2-carboxylic acid
-
-
6-bromo-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.020 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
6-chloro-7-(2,3-dihydro-1H-inden-1-ylamino)quinoline-5,8-dione
-
6-chloro-7-[(2-morpholin-4-ylethyl)amino]quinoline-5,8-dione
-
6-dibenzo(b,d)thien-1-yl-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.0076 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
6-dibenzo(b,d)thien-4-yl-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.011 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
6-fluoro-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-carboxylic acid
-
35% residual activity at 0.1 mM; 63% residual activity at 0.1 mM; 72% residual activity at 0.1 mM; 75% residual activity at 0.1 mM
6-hydroxy-2-(4-hydroxybenzyl)-3-[(1,1-biphenyl-4-yl)methyl]-4H-1-benzopyran-4-one
20% inhibition of PTP-B1 at 0.015 mM
6-hydroxy-2-phenyl-3-((3-trifluoromethyl)phenyl)benzofuran-5-carboxylic acid
-
most potent, reversible and noncompetitive inhibitor, highly selective towards isoform PTPB
6-hydroxy-3-[1-[4-(naphthalen-1-ylamino)-4-oxobutyl]-1H-1,2,3-triazol-4-yl]-2-phenyl-1-benzofuran-5-carboxylic acid
-
-
6-hydroxy-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-carboxylate
-
80% residual activity at 0.1 mM
6-hydroxy-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-carboxylic acid
-
38% residual activity at 0.1 mM; 50% residual activity at 0.1 mM; 73% residual activity at 0.1 mM
6-iodo-1-(4-methoxy-3-(methoxycarbonyl)benzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
-
IC50 of more than 20 mg/ml
6-oxo-6H-cyclohepta[b]furan-5,7-dicarboxylic acid
-
7-(2-((1H-imidazol-2-yl)thio)ethoxy)-2-phenyl-4H-chromen-4-one
-
7-(2-(1H-1,2,4-triazol-1-yl)ethoxy)-2-phenyl-4H-chromen-4-one
the inhibitor is significantly selective for enzyme protein tyrosine phosphatase 1B (PTP1B) versus other phosphatases, i.e. T-cell protein tyrosine phosphatase (TCPTP), megakaryocyte protein tyrosine phosphatase (PTP-MEG2), and src homology phosphatase 2
7-(2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethoxy)-2-phenyl-4H-chromen-4-one
-
7-(2-(4-nitro-1H-imidazol-1-yl)ethoxy)-2-phenyl-4H-chromen-4-one
-
7-(2-(5-methyl-1H-tetrazol-1-yl)ethoxy)-2-phenyl-4H-chromen-4-one
-
7-(2-bromoethoxy)-2-phenyl-4H-1-benzopyran-4-one
-
7-(3-(4-nitro-1H-imidazol-1-yl)propoxy)-2-phenyl-4H-chromen-4-one
-
7-(4-((1H-imidazol-2-yl)thio)butoxy)-2-phenyl-4H-chromen-4-one
-
7-(4-(1H-1,2,4-triazol-1-yl)butoxy)-2-phenyl-4H-chromen-4-one
-
7-(4-(2-methyl-5-nitro-1H-imidazol-1-yl)butoxy)-2-phenyl-4H-chromen-4-one
-
7-(4-(5-methyl-1H-tetrazol-1-yl)butoxy)-2-phenyl-4H-chromen-4-one
-
7-(4-bromobutoxy)-2-phenyl-4H-1-benzopyran-4-one
-
7-bromo-6-difluoromethylphosphonate 3-naphthalenenitrile
50% inhibition at 230 nM for wild-type, at 886 nM for mutant S295F
7-chloro-6-[(2-morpholin-4-ylethyl)amino]quinoline-5,8-dione
-
7-hydroxy-2-(4'-hydroxyphenyl)-3-[(1,1'-biphenyl-4-yl)methyl]-4H-1-benzopyran-4-one
-
7-hydroxy-2-(4'-hydroxyphenyl)-3-[(3'',4''-dihydroxy-1,1'-biphenyl-4-yl)methyl]-4H-1-benzopyran-4-one
-
7-hydroxy-2-(4'-hydroxyphenyl)-3-[(3''-carboxy-1,1'-biphenyl-4-yl)methyl]-4H-1-benzopyran-4-one
-
7-hydroxy-2-(4'-hydroxyphenyl)-3-[(4''-carboxy-3''-hydroxy-1,1'-biphenyl-4-yl)methyl]-4H-1-benzopyran-4-one
-
7-hydroxy-2-(4'-hydroxyphenyl)-3-[(4''-hydroxy-1,1'-biphenyl-4-yl)methyl]-4H-1-benzopyran-4-one
-
7-hydroxy-2-(4-hydroxybenzyl)-4H-chromen-4-one
10% inhibition of LMW-PTP isozymes 1 and 2,no inhibition of PTP-B1, at 0.015 mM
7-hydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-4H-chromen-4-one
-
isolated from the CH2Cl2 extract of Glycyrrhiza inflata
7-hydroxy-2-(4-hydroxyphenyl)-3-[(3',4'-dihydroxy-1,1-biphenyl-3-yl)methyl]-4H-1-benzopyran-4-one
60% inhibition of LMW-PTP isozyme 2, 25% inhibition of LMW-PTP 1, and 50% inhibition of PTP-B1, at 0.02 mM
7-hydroxy-2-(4-hydroxyphenyl)-3-[(4'-carboxy-3'-hydroxy-1,1-biphenyl-3-yl)methyl]-4H-1-benzopyran-4-one
5% inhibition of LMW-PTP isozyme 2, 10% inhibition of LMW-PTP 1, and 59% inhibition of PTP-B1, at 0.02 mM
7-hydroxy-2-(4-hydroxyphenylethyl)-3-[(1,1-biphenyl-4-yl)methyl]-4H-1-benzopyran-4-one
20% inhibition of PTP-B1 at 0.015 mM
7-hydroxy-2-(4-hydroxyphenylmethyl)-3-[(1,1'-biphenyl-4-yl)methyl]-4H-1-benzopyran-4-one
10% inhibition of PTP-B1 at 0.015 mM
7-hydroxy-2-(4-hydroxyphenylpropyl)-3-[(1,1'-biphenyl-4-yl)methyl]-4H-1-benzopyran-4-one
10% inhibition of LMW-PTP isozymes 1 and 2,no inhibition of PTP-B1, at 0.015 mM
8-acetyl-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-carboxylic acid
-
48% residual activity at 0.1 mM; 66% residual activity at 0.1 mM; 81% residual activity at 0.1 mM; 83% residual activity at 0.1 mM
8-benzyl-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.018 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
8-bromo-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-carboxylic acid
-
33% residual activity at 0.1 mM; 41% residual activity at 0.1 mM; 8% residual activity at 0.1 mM; 90% residual activity at 0.1 mM
8-bromo-4-oxo-6-(2-phenyl-1-benzothien-3-yl)-4H-chromene-3-carbaldehyde
50% inhibition at 0.0078 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
8-bromo-6-(10-bromo-9-anthryl)-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.011 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
8-bromo-6-(2-bromo-1-benzothien-3-yl)-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.0082 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
8-bromo-6-dibenzo(b,d)thien-1-yl-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.010 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
8-bromo-6-dibenzo(b,d)thien-4-yl-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.016 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
8-hydroxy-3-methoxy-11-oxo-1-pentanoyl-6-pentyl-11H-dibenzo[b,e][1,4]dioxepine-7-carboxylic acid
-
isolated from a methanol extract of the Antarctic lichen Stereocaulon alpinum
abietic acid
a nonpolar inhibitor and weak mixed-type inhibitor of PTP1B, inhibits the enzyme by binding to its active site in a nonsubstrate-like manner that stabilizes the catalytically essential WPD loop in an inactive conformation, modelling of enzyme binding. Upon binding to the active site, abietic acid forms a hydrogen bond with R221 that weakens a bond between R221 and E115 and prevents the formation of a hydrogen bond between W179 and R221 that forms when the WPD loop closes
acanthoic acid
-
diterpenoid isolated from Acanthopanax koreanum, 50% inhibition at 0.024 mM
acetaldehyde
-
more than 95% remaining activity at 0.5 mM
Acetylsalicylic acid
-
80% inhibition at 0.2 mM
acid
-
-
-
acrolein
-
4% remaining activity at 0.5 mM, potent irreversible time-dependent inhibitor, addition of 1 mM vanadate slows inactivation of PTP1B by 0.5 mM acrolein
Ammonium molybdate
antimonate
-
inhibition of protein tyrosine phosphatase activity
aquastatin A
-
derived from marine fungus Cosmospora sp. SF-5060, competitive inhibition
arsenate
-
inhibition of protein tyrosine phosphatase activity
auranofin
benzenesulfonamide
-
-
benzyl (3R,6S)-4,9-dioxo-3-[(R)-phenyl(phenylamino)methyl]-1,5-diazonane-6-carboxylate
-
-
benzyl 1,6-dibenzyl-4-oxo-1,4-dihydroquinoline-3-carboxylate
-
0.1% inhibition at 0.02 mg/ml
benzyl 1-cyclopropyl-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylate
-
80.5% inhibition at 0.02 mg/ml
benzyl oleanolic acid amide
-
benzyl oleanolic acid ester
-
Berberine
binding structure, molecular modeling, overview
betulinic acid
-
95.1% PTP1B inhibitory activity with 0.0007 mg/ml
betulinic acid methyl ester
-
89.4% PTP1B inhibitory activity with 0.00093 mg/ml
biphenyl-3,4-diol
25% inhibition of LMW-PTP isozyme 2, and 10% inhibition of LMW-PTP 1 and PTP-B1 at 0.02 mM
bis(2-ethyl-maltolato)oxidovanadium(IV)
noncompetitive inhibition of hydrolysis of 4-nitrophenyl phosphate and of phosphorylated undecapeptide substrate EGFR988-998 in the presence of bis(2-ethyl-maltolato)oxidovanadium(IV)
bis(2-methyl-maltolato)oxidovanadium(IV)
-
bis(3-hydroxy-2-methyl-4(1H)pyridinonato)oxidovanadium(IV)
-
bis(acetylacetonato)oxidovanadium(IV)
acts as an uncompetitive inhibitor of PTP1B with DADEpYLIPQQG as the substrate, but this VO2+-chelate exhibits only apparent competitive inhibition of 4-nitrophenyl phosphate hydrolysis when catalyzed by PTP1B, differing from that observed in the hydrolysis of the phosphotyrosine-containing undecapeptide DADEpYLIPQQG mimicking residues 988-998 of the epidermal growth factor receptor (EGFR). Addition of 4-nitrophenyl phosphate after addition of saturating amounts of bis(acetylacetonato)oxidovanadium(IV) to PTP1B causes complete loss of catalytic activity
BzN-EJJ-amide
calopocarpin
-
-
cantharidin
-
17% inhibition at 1 mM
chloro(1,3-dimethyl-1,3-dihydro-2H-imidazol-2-ylidene)gold
-
i.e. [(p-MeMeIm)AuICl]
chloro(1-methyl-1,3-dihydro-2H-imidazol-2-ylidene)gold
-
i.e. [(MeIm)AuICl]
chloro[1-methyl-3-(4-methylbenzyl)-2,3-dihydro-1H-imidazol-2-yl]gold
-
i.e. [(p-MeBzMeIm)AuICl]
CinnGel 2ME
continentalic acid
modelling of enzyme binding
corosolic acid
-
50% inhibition at 0.0072mM, mixed-type inhibition
Cr(VI)
-
as Na2CrO4, induces clonogenic lethality
crotonaldehyde
-
85% remaining activity at 0.5 mM
cyclopropyl-6-(4-fluorobenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
-
71.1% inhibition at 0.02 mg/ml
dehydroabietic acid
modelling of enzyme binding
dehydrocostuslactone
-
86.2% PTP1B inhibitory activity with 0.00651 mg/ml
dephostatin
diethylcarbamazine
-
12% inhibition at 0.2 mM
diethyldicarbonate
-
7% inhibition at 1 mM
Differentiation inducing factor 1
-
DIF-1, inhibits PTP3 by induction of serine-threonine phosphorylation of PTP3
-
dihydroabietic acid
modelling of enzyme binding
diphosphate
disodium 3-(((4-methyl-3-(((2-methyl-5-((3-sulfonatophenyl)carbamoyl)phenyl)carbamoyl)amino)phenyl)carbonyl)amino)benzenesulfonate
-
suramin-derivative, 50% inhibition at 0.030 mM, reversible and competitive
disodium 4-(((4-methyl-3-(((3-(((3-((2-methyl-5-((4-sulfonatophenyl)carbamoyl)phenyl)carbamoyl)phenyl)carbamoyl)amino)phenyl)carbonyl)amino)phenyl)carbonyl)amino)benzenesulfonate
disodium hydrogen (3-(((4-(((4-((3-(hydroxyphosphinato)phenyl)carbamoyl)phenyl)carbamoyl)amino)phenyl)carbonyl)amino)phenyl)phosphonate
dithiothreitol
DTT
-
inhibition of cytosolic enzyme form
dysidiolide
inhibits Cdc25A
EDTA
-
51% inhibition at 5 mM
ent-17-hydroxykaur-15-en-19-oic acid
40% inhibition at 0.033 mM
ent-3beta-angeloyloxykaur-16-en-19-oic acid
-
ent-3beta-tigloyloxykaur-16-en-19-oic acid
-
ent-kaur-16-en-19-oic acid
-
diterpenoid isolated from Acanthopanax koreanum, 50% inhibition at 0.020 mM
ent-kaur-9(11),16-dien-19-oic acid
29% inhibition at 0.033 mM
erybraedin A
-
-
erylysins A
-
i.e. 3''-hydroxy-2',2'-dimethylpyrano[6',5':3,4]-2'',2''-dimethyldihydropyrano[6'',5'':9,10]pterocarpan, a pterocarpan isolated from stem bark of Erythrina lysistemon, inhibits PTPB1
erylysins B
-
i.e. furano[5',4':3,4]-9-hydroxy-10-prenylpterocarpan, a pterocarpan isolated from stem bark of Erythrina lysistemon, inhibits PTPB1
erysubin D
-
-
eryvarin D
-
-
ethyl (4R)-4-[(1R,3aS,3bS,10aR,10bS,12aR)-6,6,10a,12a-tetramethyl-1,2,3,3a,3b,4,6,6a,7,9a,10,10a,10b,11,12,12a-hexadecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-yl]pentanoate
-
-
ethyl (4R)-4-[(1R,3aS,3bS,11aR,11bS,13aR)-8-amino-6,6,11a,13a-tetramethyl-2,3,3a,3b,4,6,11,11a,11b,12,13,13a-dodecahydro-1H-cyclopenta[5,6]naphtho[1,2-g]quinazolin-1-yl]pentanoate
-
-
ethyl 4-[4-[(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)prop-2-enoyl]phenoxy]butanoate
-
-
ethyl [4-[(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)prop-2-enoyl]phenoxy]acetate
-
-
ethyl-3,4-dephostatin
-
FlAsH
the small molecule biarsenical fluorescein derivative, FlAsH, is no inhibitor of the wild-type enzyme but of the engineered WPD insertion mutant enzyme that displays FlAsH-binding cysteine residues. Inhibition of the FlAsH-sensitized TCPTP mutants is rapid and specific, and strong FlAsH sensitivity is observed in mutants that contain as few as two cysteine point mutations in their engineered WPD loops, minimization of FlAsH-binding determinants, overview
fluorescein arsenical hairpin binder
fluorescein arsenical hairpin binder does not inhibit any wild type PTP, but insertion of a fluorescein arsenical hairpin binder-binding peptide (CCPGCC) at a conserved position in the PTP catalytic-domain's WPD loop confers fluorescein arsenical hairpin binder sensitivity upon divergent PTPs
-
formaldehyde
-
-
glycyrrhetic acid
-
-
Glyoxal
-
93% remaining activity at 0.5 mM
glyoxalbis(N(4)-methylthiosemicarbazonato)Cu(II)
-
inhibition of protein tyrosine phosphatase activity is the prerequisite for activation of epidermal growth factor receptor by the compound, overview
heparin
hexadecanoyl-5-hydroxymethyl tetronic acid
potent irreversible inhibitor of VHR; potent irreversible inhibitor of VHR; potent irreversible inhibitor of VHR
hexasodium 8,8'-(((2E)-1,4-dioxobut-2-ene-1,4-diyl)bis(iminobenzene-3,1-diylcarbonylimino(4-methylbenzene-3,1-diyl)carbonylimino))dinaphthalene-1,3,5-trisulfonate
hexasodium 8,8'-(benzene-1,3-diylbis(carbonyliminobenzene-3,1-diylcarbonylimino(4-methylbenzene-3,1-diyl)carbonylimino))dinaphthalene-1,3,5-trisulfonate
hexasodium 8-(((2'-(((3'-((4,6,8-trisulfonatonaphthalen-1-yl)carbamoyl)biphenyl-2-yl)carbamoyl)amino)biphenyl-4-yl)carbonyl)amino)naphthalene-1,3,5-trisulfonate
hexasodium 8-(((3-methyl-4-(((3-(((3-((2-methyl-4-((4,6,8-trisulfonatonaphthalen-1-yl)carbamoyl)phenyl)carbamoyl)phenyl)carbamoyl)amino)phenyl)carbonyl)amino)phenyl)carbonyl)amino)naphthalene-1,3,5-trisulfonate
hexasodium 8-(((3-methyl-4-(((4-(((4-((4-((4,6,8-trisulfonatonaphthalen-1-yl)carbamoyl)phenyl)carbamoyl)phenyl)carbamoyl)amino)phenyl)carbonyl)amino)phenyl)carbonyl)amino)naphthalene-1,3,5-trisulfonate
hexasodium 8-(((4-(((3-(((3-((4-((4,6,8-trisulfonatonaphthalen-1-yl)carbamoyl)phenyl)carbamoyl)phenyl)carbamoyl)amino)phenyl)carbonyl)amino)phenyl)carbonyl)amino)naphthalene-1,3,5-trisulfonate
hexasodium 8-(((4-(1-methylethyl)-3-(((3-(((3-((2-(1-methylethyl)-5-((4,5,8-trisulfonatonaphthalen-1-yl)carbamoyl)phenyl)carbamoyl)phenyl)carbamoyl)amino)phenyl)carbonyl)amino)phenyl)carbonyl)amino)naphthalene-1,4,5-trisulfonate
hexasodium 8-(((4-ethyl-3-(((3-(((3-((2-ethyl-5-((4,5,8-trisulfonatonaphthalen-1-yl)carbamoyl)phenyl)carbamoyl)phenyl)carbamoyl)amino)phenyl)carbonyl)amino)phenyl)carbonyl)amino)naphthalene-1,4,5-trisulfonate
hexasodium 8-(((4-tert-butyl-3-(((3-(((3-((2-tert-butyl-5-((4,5,8-trisulfonatonaphthalen-1-yl)carbamoyl)phenyl)carbamoyl)phenyl)carbamoyl)amino)phenyl)carbonyl)amino)phenyl)carbonyl)amino)naphthalene-1,4,5-trisulfonate
hexasodium 8-([[2-(3-[[(3-[5-[(4,6,8-trisulfonatonaphthalen-1-yl)carbamoyl]-1H-benzimidazol-2-yl]phenyl)carbamoyl]amino]phenyl)-1H-benzimidazol-5-yl]carbonyl]amino)naphthalene-1,3,5-trisulfonate
HgCl2
-
-
iodoacetate
-
-
iodoacetic acid
ISIS 113715
-
isoneorautenol
-
-
isopimaric acid
modelling of enzyme binding
JTT-551
L-(+)-Tartrate
-
6.5% inhibition at 5 mM
L-phenylalanine
-
-
L-Tartrate
licochalcone E
-
lithocholic acid
-
natural inhibitor against PTP1B
lobaric acid
-
a depsidone-type compound, isolated from a methanol extract of the Antarctic lichen Stereocaulon alpinum
lupenone
-
isolated from Sorbus commixta stem bark, inhibits PTP1B in a selective and noncompetitive manner
lupeol
-
isolated from Sorbus commixta stem bark, inhibits PTP1B in a selective and noncompetitive manner
maslinic acid
menadione
inhibits Cdc25B irreversibly
methyl (4R)-4-[(1R,3aS,3bS,10aR,10bS,12aR)-8-amino-6,6,10a,12a-tetramethyl-2,3,3a,3b,4,6,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[2,3-d][1,3]thiazol-1-yl]pentanoate
-
-
methyl (4R)-4-[(1R,3aS,3bS,11aR,11bS,13aR)-6,6,11a,13a-tetramethyl-2,3,3a,3b,4,6,11,11a,11b,12,13,13a-dodecahydro-1H-cyclopenta[5,6]naphtho[1,2-g]quinoxalin-1-yl]pentanoate
-
-
methyl (6S,10S)-12-(2-chloro-3-hydroxybenzyl)-9-oxo-6,7,8,9,10,11-hexahydro-5H-6,10-epiminocycloocta[b]indole-8-carboxylate
-
-
methyl (6S,10S)-12-(2-fluoro-5-iodobenzyl)-9-oxo-6,7,8,9,10,11-hexahydro-5H-6,10-epiminocycloocta[b]indole-8-carboxylate
-
-
methyl (6S,10S)-12-(2-hydroxybenzyl)-9-oxo-6,7,8,9,10,11-hexahydro-5H-6,10-epiminocycloocta[b]indole-8-carboxylate
-
absolutely specific for MptpB, no inhibition of MptpA
methyl (6S,10S)-12-(3,4-dichlorobenzyl)-9-oxo-6,7,8,9,10,11-hexahydro-5H-6,10-epiminocycloocta[b]indole-8-carboxylate
-
absolutely specific for MptpB, no inhibition of MptpA
methyl (6S,10S)-12-(3,4-difluorobenzyl)-9-oxo-6,7,8,9,10,11-hexahydro-5H-6,10-epiminocycloocta[b]indole-8-carboxylate
-
-
methyl (6S,10S)-12-(3-bromo-4-fluorobenzyl)-9-oxo-6,7,8,9,10,11-hexahydro-5H-6,10-epiminocycloocta[b]indole-8-carboxylate
-
absolutely specific for MptpB, no inhibition of MptpA
methyl (6S,10S)-12-(3-hydroxybenzyl)-9-oxo-6,7,8,9,10,11-hexahydro-5H-6,10-epiminocycloocta[b]indole-8-carboxylate
-
absolutely specific for MptpB, no inhibition of MptpA
methyl (6S,10S)-12-benzyl-9-oxo-6,7,8,9,10,11-hexahydro-5H-6,10-epiminocycloocta[b]indole-8-carboxylate
-
-
methyl (6S,10S)-12-[(4,6-dichloro-2H-chromen-3-yl)methyl]-9-oxo-6,7,8,9,10,11-hexahydro-5H-6,10-epiminocycloocta[b]indole-8-carboxylate
-
absolutely specific for MptpB, no inhibition of MptpA
methyl (6S,10S)-12-[(4-chloro-6-fluoro-2H-chromen-3-yl)methyl]-9-oxo-6,7,8,9,10,11-hexahydro-5H-6,10-epiminocycloocta[b]indole-8-carboxylate
-
absolutely specific for MptpB, no inhibition of MptpA, inhibition kinetics, overview
methyl (6S,10S)-12-[(5-chloro-1H-indol-3-yl)methyl]-9-oxo-6,7,8,9,10,11-hexahydro-5H-6,10-epiminocycloocta[b]indole-8-carboxylate
-
absolutely specific for MptpB, no inhibition of MptpA
methyl (6S,10S)-12-[(5-methylfuran-2-yl)methyl]-9-oxo-6,7,8,9,10,11-hexahydro-5H-6,10-epiminocycloocta[b]indole-8-carboxylate
-
absolutely specific for MptpB, no inhibition of MptpA
methyl (6S,10S)-9-hydroxy-12-(3-hydroxybenzyl)-6,7,8,9,10,11-hexahydro-5H-6,10-epiminocycloocta[b]indole-8-carboxylate
-
-
methyl (6S,10S)-9-oxo-12-(pyridin-3-ylmethyl)-6,7,8,9,10,11-hexahydro-5H-6,10-epiminocycloocta[b]indole-8-carboxylate
-
-
methyl 2,4-dihydroxy-6-methylbenzoate
-
isolated from a methanol extract of the Antarctic lichen Stereocaulon alpinum
methyl 2-(3-(1-(4-fluorobenzyl)-6-nitro-4-oxo-1,4-dihydroquinoline-3-carboxamido)propoxy)-6-hydroxybenzoate
-
IC50 of 6.5 mg/ml
methyl 2-(3-(1-benzyl-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxamido)propoxy)-6-hydroxybenzoate
-
IC50 of 9.4 mg/ml
methyl 2-[4-[(4-[[ethoxy(oxo)acetyl][2-(methoxycarbonyl)phenyl]amino]-3-ethylphenylalanyl)amino]butoxy]-6-hydroxybenzoate
-
methyl 3,8-dimethoxy-11-oxo-1-pentanoyl-6-pentyl-11H-dibenzo[b,e][1,4]dioxepine-7-carboxylate
-
isolated from a methanol extract of the Antarctic lichen Stereocaulon alpinum
methyl 3-formyl-2,4-dihydroxy-6-methylbenzoate
-
isolated from a methanol extract of the Antarctic lichen Stereocaulon alpinum
methyl 4,4-dimethyl-3-oxochol-5-en-24-oate
-
-
methyl 4-[(benzylseleninyl)methyl]-N-(tert-butoxycarbonyl)-L-phenylalaninate
-
-
methyl 5-amino-6-(7-amino-6-methoxy-5,8-dioxo-5,8-dihydroquinolin-2-yl)-4-(2-hydroxy-3,4-dimethoxyphenyl)-3-methylpyridine-2-carboxylate
-
methyl 8-hydroxy-3-methoxy-11-oxo-1-pentanoyl-6-pentyl-11H-dibenzo[b,e][1,4]dioxepine-7-carboxylate
-
isolated from a methanol extract of the Antarctic lichen Stereocaulon alpinum
methyl N-(tert-butoxycarbonyl)-4-(hydroxymethyl)-L-phenylalaninate
-
-
methyl N-(tert-butoxycarbonyl)-4-[(5R)-5-(methoxycarbonyl)-9,9-dimethyl-7-oxo-8-oxa-3-thia-2-selena-6-azadec-1-yl]-L-phenylalaninate
-
-
methyl oleanolic acid amide
-
methyl oleanolic acid ester
-
methyl-5-((3-(benzylcarbamoyl)-6-iodo-4-oxoquinolin-1(4H)-yl)methyl)-2-methoxybenzoate
-
IC50 of more than 20 mg/ml
mokko lactone
-
93.1% PTP1B inhibitory activity with 0.00141 mg/ml
molybdate
mpV(pic)
-
potent and selective PTP inhibitor, inhibits SPH-1 in a dose-dependent manner
MSI-1436
small molecule inhibitor MSI-1436 binds to the disordered C-terminal domain of PTP1B, C-terminal to the catalytic domain, MSI-1436 functions using an allosteric mechanism to direct the enzymatic activity of PTP1B
N,1-dibenzyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxamide
-
41.4% inhibition at 0.02 mg/ml
N,1-dibenzyl-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxamide
-
61.8% inhibition at 0.02 mg/ml
N,N'-[benzene-1,4-diylbis(propane-2,2-diylbenzene-4,1-diyl)]bis(1,1,1-trifluoromethanesulfonamide)
-
-
N-((4-((E)-2-nitroethenyl)phenyl)carbonyl)glycyl-L-alpha-glutamyl-L-glutamic acid
-
50% inhibition at 0.0014 mM in absence of 2-mercaptoethanol, at 0.275 mM in presence of 1 mM 2-mercaptoethanol
N-((4-(difluoro(phosphono)methyl)phenyl)acetyl)-L-a-aspartyl-4-(difluoro(phosphono)methyl)-L-phenylalaninamide
-
inhibition of enzyme increases caveolin-1 phosphorylation
N-((4-(difluoro(phosphono)methyl)phenyl)acetyl)-L-alpha-aspartyl-4-(difluoro(phosphono)methyl)-L-phenylalaninamide
-
-
N-(1,4-dioxo-1,4-dihydronaphthalen-2-yl)-N-(4-methylphenyl)acetamide
-
N-(3-chloro-4-fluorophenyl)-2-[(6,7-dimethoxy-4-oxo-3-phenyl-3,4-dihydro-2-quinazolinyl)sulfanyl]acetamide
80% inhibition at 0.2 mM
N-(3-formylphenyl)-3-(((3-((3-formylphenyl)carbamoyl)phenyl)carbamoyl)amino)benzamide
N-(3-[(3,5-difluorobenzyl)oxy]pyridin-2-yl)-4-pentylbenzenesulfonamide
74% inhibition at 0.2 mM
N-(3-[(4-chlorophenyl)sulfanyl]-1,4-dioxo-1,4-dihydronaphthalen-2-yl)acetamide
-
N-(4-([(6-ethoxy-1,3-benzothiazol-2-yl)amino]sulfonyl)phenyl)acetamide
-
-
N-(4-([(6-methoxy-1,3-benzothiazol-2-yl)amino]sulfonyl)phenyl)acetamide
-
-
N-(4-([(6-methyl-1,3-benzothiazol-2-yl)amino]sulfonyl)phenyl)acetamide
-
-
N-(4-[[(6-nitro-1,3-benzothiazol-2-yl)amino]sulfonyl]-phenyl)acetamide
-
-
N-(6-chloro-1,3-benzothiazol-2-yl)-4-nitrobenzenesulfonamide
-
-
N-(6-ethoxy-1,3-benzothiazol-2-yl)-4-methoxybenzenesulfonamide
-
-
N-(6-ethoxy-1,3-benzothiazol-2-yl)-4-methylbenzenesulfonamide
-
-
N-(6-ethoxy-1,3-benzothiazol-2-yl)-4-nitrobenzene sulfonamide
-
linear mixed-type inhibition, shows in vivo antihyperglycemic activity
N-(6-ethoxy-1,3-benzothiazol-2-yl)benzenesulfonamide
-
-
N-(6-fluoro-1,3-benzothiazol-2-yl)-4-nitrobenzenesulfonamide
-
-
N-(6-methoxy-1,3-benzothiazol-2-yl)-4-methylbenzenesulfonamide
-
-
N-(6-methoxy-1,3-benzothiazol-2-yl)-4-nitrobenzenesulfonamide
-
-
N-(6-methoxy-1,3-benzothiazol-2-yl)benzenesulfonamide
-
-
N-(6-methyl-1,3-benzothiazol-2-yl)-4-nitrobenzenesulfonamide
-
linear mixed-type inhibition, shows in vivo antihyperglycemic activity
N-(6-methyl-1,3-benzothiazol-2-yl)benzenesulfonamide
-
-
N-([4-[difluoro(phosphono)methyl]phenyl]acetyl)-a-aspartyl-4-[difluoro(phosphono)methyl]phenylalaninamide
-
-
N-1-(2-[(2-oxo-4-propyl-2H-chromen-7-yl)oxy]propanoyl)-3-(trifluoromethyl)benzene-1-sulfonohydrazide
84% inhibition at 0.2 mM
N-benzoyl-L-glutamyl-[4-phosphono(difluoromethyl)]-L-phenylalanineamide
-
i.e. BzN-EJJ-amide, 50% inhibition at 4 nM
N-benzyl-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxamide
-
0.2% inhibition at 0.02 mg/ml; 7.4% inhibition at 0.02 mg/ml
N-benzyl-1-cyclopropyl-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxamide
-
6.1% inhibition at 0.02 mg/ml
n-dodecyl trimethylammonium bromide
-
pH 7.0, inactivation at concentration 10fold higher than critical micellar concentration
N-ethylmaleimide
n-hexadecyl trimethylammonium bromide
-
pH 7.0, inactivation at concentration 10fold higher than critical micellar concentration
N-Methylmaleimide
-
76.3% inhibition at 0.5 mM
n-tetradecyl trimethylammonium bromide
-
pH 7.0, inactivation at concentration 10fold higher than critical micellar concentration
N-[4-[(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)prop-2-enoyl]phenyl]-4-tert-butylbenzamide
-
-
N-[5-(dimethylamino)-2-hydroxy-3-methoxybenzyl]-N-methyl-2-(4-nitrophenyl)ethanaminium
-
N-[6-chloro-5-(2,3-dichlorophenoxy)-1-methyl-1H-benzimidazol-2-yl]acetamide
70% inhibition at 0.2 mM
N-[6-chloro-5-(2,3-dichlorophenoxy)-1H-benzimidazol-2-yl]-2,2,2-trifluoroacetamide
mixed-type inhibition, 92% inhibition at 0.2 mM
N2-(2-((2-((N-((4-(difluoro(phosphono)methyl)phenyl)acetyl)-L-alpha-aspartyl-4-(difluoro(phosphono)methyl)-L-phenylalanyl)amino)ethyl)disulfanyl)ethyl)-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-argininamide
-
in presence of 5-50 nM, 11-35% decrease in cell spreading, 24% decrease in number of migratory cells, dose-dependent increase in Y527 phosphorylation of Src
Na+/K+ tartrate
-
20% residual activity in ovary and 2% residual activity in haemolymph at 10 mM
Na3VO4
NAT6-297775
-
-
Ni2+
-
-
NO
-
inactivation, phosphate protects
nocardione A
inhibits Cdc25B
nocardione B
inhibits Cdc25B
NSC-87877
-
potent Shp2 and Shp1 inhibitor
o-vanadate
okadaic acid
oleanolic acid
oleanolic acid amide
-
oleanolic alcohol
-
oleanonic acid
-
-
orientanol C
-
-
orthovanadate
p-chloromercuribenzoate
-
lung enzyme
p-hydroxymercuribenzoate
-
p-nitrocatechol sulfate
-
competitive inhibitor
PAO
complete inhibition at 0.0.5 mM
papaverine
binding structure, molecular modeling, overview
paracaseolide A
-
-
peracetic acid
-
a potent, time-dependent inactivator of the catalytic subunit of PTP1B, treatment of the enzyme with 0.015 mM for 15 sec inactivates 88% of the enzyme, inactivation of PTP1B by peracetic acid can be reversed by treatment of the enzyme with thiols
pervanadate
phaseollin
-
-
phenyl vinyl sulfonate
-
phenyl vinyl sulfonate-mediated PTP inactivation is active site-directed and irreversible
phenyl vinyl sulfone
-
phenyl vinyl sulfone-mediated PTP inactivation is active site-directed and irreversible
Phenylarsine oxide
phenylhydrazonopyrazolone sulfonate 1
-
potent, active site-directed small molecule inhibitor which is specific for Shp2 over the closely related tyrosine phosphatases Shp1 and PTP1B
phenylhydrazonopyrazolone sulfonate 4
-
the most potent inhibitor of Shp2 which shows a specificity profile similar to phenylhydrazonopyrazolone sulfonate 1
phosphate
phosphotyrosine
PO43-
poly(Glu-Tyr)
-
-
pomolic acid
-
-
potassium bisperoxo(1,10-phenanthroline)oxovanadate
potassium bisperoxo(1,10-phenanthroline)oxovanadate(V)
-
i.e. [bpV(phen)], the peroxovanadium compound is a stable, potent and selective protein tyrosine phosphatase inhibitor. It protects dorsal column sensory axons and white matter and rescues sensory-evoked potentials in vivo after treatement with PTP or spinal cord injury, overview
propanal
-
93% remaining activity at 0.5 mM
pterokaurene L3
no inhibition at 0.031 mM
regucalcin
-
regulatory protein in intracellular signaling
-
rilobolide-6-O-methacrylate
no inhibition at 0.026 mM
RK-682
rotungenic acid
-
-
S-nitrosoglutathione
-
S-nitrosoglutathione treatment decreases the catalytic activity parameters of PtpA by half
SK7
-
a metal chalcone, complete inhibition at 0.02 mM
small t antigen
-
small t antigen of DNA tumor virus SV40 inhibits the phosphatase activity of the PP2A core enzyme
-
sodium decylsulfate
-
at concentration 10fold lower than critical micellar concentration, complete inactivation. Inactivation is independent of pH-value, irreversible and not affected by NaCl. Presence of phosphate protects
Sodium diphosphate
-
both isoforms, inhibition by millimolar concentrations
sodium dodecylsulfate
-
at concentration 10fold lower than critical micellar concentration, complete inactivation. Inactivation is independent of pH-value, irreversible and not affected by NaCl. Presence of phosphate protects
Sodium fluoride
sodium octylsulfate
-
at concentration 10fold lower than critical micellar concentration, complete inactivation. Inactivation is independent of pH-value, irreversible and not affected by NaCl. Presence of phosphate protects
sodium ortho-vanadate
-
sodium orthovanadate
sodium pervanadate
-
broad-acting tyrosine phosphatase inhibitor
Sodium tetradecylsulfate
-
at concentration 10fold lower than critical micellar concentration, complete inactivation. Inactivation is independent of pH-value, irreversible and not affected by NaCl. Presence of phosphate protects
sodium tungstate
-
complete inhibition of enzyme isolated from metacyclic stage, 50% inhibition of enzyme from procyclic stage
Sodium vanadate
spathodic acid
-
-
spermidine
-
-
spermine
-
2.0-20 mM
stevastelin
inhibits VHR; inhibits VHR; inhibits VHR
stigmasterol
-
-
sulfircin
inhibits Cdc25A
suramin
taraxerol
-
-
Tartrate
-
both SynPPP1 and SYnPPM3
tetrachyrin
-
tetramisole
-
both SynPPP1 and SYnPPM3
tetrasodium 2-(((2-(3-(((3-(5-((2,5-disulfonatophenyl)carbamoyl)-1H-benzimidazol-2-yl)phenyl)carbamoyl)amino)phenyl)-1H-benzimidazol-5-yl)carbonyl)amino)benzene-1,4-disulfonate
tetrasodium 4,4'-(benzene-1,3-diylbis(carbonylimino))dinaphthalene-2,6-disulfonate
tetrasodium 4,4'-(benzene-1,3-diylbis(carbonyliminobenzene-4,1-diylcarbonylimino))dinaphthalene-2,6-disulfonate
tetrasodium 4-(((3-(((3,5-bis((4-sulfonatophenyl)carbamoyl)phenyl)carbamoyl)amino)-5-((4-sulfonatophenyl)carbamoyl)phenyl)carbonyl)amino)benzenesulfonate
tetrasodium 4-(((3-(((5-((4,8-disulfonatonaphthalen-1-yl)carbamoyl)-2-methylphenyl)carbamoyl)amino)-4-methylphenyl)carbonyl)amino)naphthalene-1,5-disulfonate
Trifluoperazine
-
complete inhibition of enzyme isolated from metacyclic stage, 18% inhibition of enzyme from procyclic stage
trilobolide-6-O-isobutyrate
no inhibition at 0.026 mM
tungstate
ursolic acid
uvaol
-
-
vanadate
VO3N3
-
oxovanadium(IV) is coordinated with one nitrogen and two oxygen atoms from the Schiff base and two nitrogen atoms from the bidentate planar ligands, in a distorted octahedral geometry, VO3N3
wedelolide D
32% inhibition at 0.020 mM
wedelolide H
no inhibition at 0.023 mM
wedelolide I
no inhibition at 0.021 mM
wedelolide J
no inhibition at 0.021 mM
[(1-benzyl-1H-indazol-5-yl)(difluoro)methyl]phosphonic acid
-
[(2-benzyl-2H-indazol-5-yl)(difluoro)methyl]phosphonic acid
-
[(4-bromophenyl)(difluoro)methyl]phosphonic acid
-
[(4-[(4E)-2-(1H-benzotriazol-1-yl)-2-[4-(methoxycarbonyl)phenyl]-5-phenylpent-4-en-1-yl]phenyl)(difluoro)methyl]phosphonic acid
-
[(4-[[3,5-bis(trifluoromethyl)phenyl]carbamoyl]phenyl)(difluoro)methyl]phosphonic acid
-
[(4-[[4-bromo-3,5-bis(trifluoromethyl)phenyl]carbamoyl]phenyl)(difluoro)methyl]phosphonic acid
selectivity with different PTPs, overview
[(4-[[4-bromo-3-(trifluoromethyl)phenyl]carbamoyl]phenyl)(difluoro)methyl]phosphonic acid
-
[(4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl]phenyl)(difluoro)methyl]phosphonic acid
-
[(BzMeIm)Au(I)Cl]
Yersinia enterolytica
-
-
[(MeIm)Au(I)Cl]
Yersinia enterolytica
-
-
[(MeMeIm)Au(I)Cl]
Yersinia enterolytica
-
-
[(p-MeBzMeIm)Au(I)Cl]
Yersinia enterolytica
-
-
[2-bromo-4-[(E)-(7,8-dimethyl-3-oxo[1,3]thiazolo[3,2-a]benzimidazol-2(3H)-ylidene)methyl]-6-ethoxyphenoxy]acetic acid
irreversible inhibition
[4-[(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)prop-2-enoyl]phenoxy]acetic acid
-
-
[biphenyl-4-yl(difluoro)methyl]phosphonic acid
-
[difluoro(4-nitrophenyl)methyl]phosphonic acid
-
[difluoro(4-[[2-(trifluoromethyl)phenyl]carbamoyl]phenyl)methyl]phosphonic acid
-
[difluoro(4-[[3-(trifluoromethyl)phenyl]carbamoyl]phenyl)methyl]phosphonic acid
-
[difluoro(4-[[4-(trifluoromethyl)phenyl]carbamoyl]phenyl)methyl]phosphonic acid
-
[difluoro(4-[[4-fluoro-3-(trifluoromethyl)phenyl]carbamoyl]phenyl)methyl]phosphonic acid
-
[difluoro[3-(phenylcarbamoyl)phenyl]methyl]phosphonic acid
-
[difluoro[4-(1,3-thiazol-2-ylcarbamoyl)phenyl]methyl]phosphonic acid
-
[difluoro[4-(1-methyl-1H-pyrazol-4-yl)phenyl]methyl]phosphonic acid
-
[difluoro[4-(methylcarbamoyl)phenyl]methyl]phosphonic acid
-
[difluoro[4-(phenoxymethyl)phenyl]methyl]phosphonic acid
-
[difluoro[4-(phenylcarbamoyl)phenyl]methyl]phosphonic acid
-
[difluoro[4-(phenylsulfamoyl)phenyl]methyl]phosphonic acid
-
[difluoro[4-(propan-2-ylcarbamoyl)phenyl]methyl]phosphonic acid
-
[RuIII(EDTA)(OH2/OH)]1-/2-
-
RuIII-EDTA inhibits PTP, like vanadate, through an oxidant-independent pathway. It inhibits PTP at physiological pH values by a mechanism that involves binding of the Cys residue of the catalytic domain of the enzyme, overview. At pH 7.4, the Ru-EDTA complex exists as a mixture of aqua and hydroxo-species. The inhibition is reversible or inhibited by glutathione
-
[[1-(4-chlorophenyl)-2-methyl-1H-indol-5-yl]oxy]acetic acid
-
[[4'-(2-butyl-1-benzofuran-3-yl)biphenyl-4-yl]oxy]acetic acid
-
[[4-(1H-benzimidazol-2-ylcarbamoyl)phenyl](difluoro)methyl]phosphonic acid
-
[[4-(benzoylamino)phenyl](difluoro)methyl]phosphonic acid
-
[[4-(benzylcarbamoyl)phenyl](difluoro)methyl]phosphonic acid
-
[[4-([[3,5-bis(trifluoromethyl)phenyl]carbamoyl]amino)phenyl](difluoro)methyl]phosphonic acid
-
[[4-[(1-ethylpiperidin-4-yl)carbamoyl]phenyl](difluoro)methyl]phosphonic acid
-
[[4-[(2-bromophenyl)carbamoyl]phenyl](difluoro)methyl]phosphonic acid
-
[[4-[(2-chlorophenyl)carbamoyl]phenyl](difluoro)methyl]phosphonic acid
-
[[4-[(3-bromophenyl)carbamoyl]phenyl](difluoro)methyl]phosphonic acid
-
[[4-[(3-chlorophenyl)carbamoyl]phenyl](difluoro)methyl]phosphonic acid
-
[[4-[(4-bromophenyl)carbamoyl]phenyl](difluoro)methyl]phosphonic acid
-
[[4-[(4-chlorophenyl)carbamoyl]phenyl](difluoro)methyl]phosphonic acid
-
additional information
-